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INTRODUCTION 
Dengue infections are currently one of the most rapidly emerging arboviral 
infections in the world, which result in 390 million infections every year 
(1)
. They 
cause significant morbidity and mortality especially in developing countries and is 
a huge burden on their economies. 
 Although the majority of dengue infections result in asymptomatic infection or 
manifest as undifferentiated viral fever, some develop fluid leakage and bleeding 
manifestations which result in dengue haemorrhagic fever (DHF) and dengue 
shock syndrome (DSS.) 
As there is no effective antiviral treatment or a licensed vaccine to prevent 
infection, meticulous fluid management and monitoring for complications is 
currently the only option available. 
Earlier case fatalities due to dengue infection have been reported to be around 
2.5% to 5.4% 
(1)
. Shock and organ impairment have been shown to be the most 
important factors that lead to fatalities in dengue infection.  
As a result of better fluid management regimens and greater awareness of 
associations of severe dengue and early interventions, the case fatality rates have 
significantly dropped in many dengue endemic countries. However, in order for 
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early detection of those who are likely to develop severe dengue, the clinical and 
laboratory parameters are measured at least two or three times a day in all patients 
admitted to the hospital with dengue infection. 
 Although ideal management of children includes monitoring of many clinical 
parameters at least every 2 hours, this is sometimes impossible due to limited 
health resources. Therefore, a simple test that can be done in a ward would be of 
utmost importance to determine the children who are most likely to develop severe 
clinical disease. 
Early diagnosis and prompt treatment can help in reducing significant mortality 
and our study has attempted to identify a predictor of severe dengue. 
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AIM AND OBJECTVES 
AIM  
  To assess the role of  NS1 antigen Assay in the management of dengue fever 
in children 
 
OBJECTIVE 
To assess the utility of NS1 antigen assay in predicting severity of dengue 
fever in children by estimating titres. 
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MATERIALS AND METHODOLOGY 
 
STUDY DESIGN: Hospital based prospective observational study  
 
PLACE OF STUDY: PSG Hospitals,  PSGIMS&R , Coimbatore 
 
TIME PERIOD: January 2016 to May 2017 
 
SAMPLE SIZE: 250 samples were required based on the formula 4p9/d2 
considering the prevalence of dengue fever  
 
INCLUSION CRITERIA: 
 Age: less than 18 years 
 Study was carried out in children with clinical suspicion of dengue fever 
with features like 
 Fever > 3 days 
 Myalgia 
 Rash 
 Arthralgia 
EXCLUSION CRITERIA 
 Children with  dengue fever and  co infections were excluded . 
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METHODOLOGY 
Ethical committee approval was obtained and  Prospective collection of data 
was done in children who fulfilled the inclusion criteria in the Pediatrics 
department at tertiary care centre, PSGIMSR, Coimbatore where  systematic  
computer  coding  for  registry is  used. NS1 Antigen ELISA was done in all 
children between day 1 to 5 illness  who fulfilled the inclusion criteria and 2ml of 
blood was drawn and collected in EDTA container. NS1 Antigen ELISA was 
tested using (J-Mithra kit)India at the Serology lab in our hospital. Qualitative and 
semi Quantitative analysis was done. 
 
   Titre of >11 was considered  strongly positive, 9-11 as equivocal and titre 
value of 9 was mild positive. Dengue Serology for IgG antibodies for secondary 
infection and  IgM antibodies  for primary infection were performed on the same 
children using ELISA Assay. All other relevant  and additional investigations were 
done as per the course of illness. 
 
Data was entered in structured proforma and case definition, diagnosis and 
management used for dengue fever were categorized into Mild, Moderate and 
Severe dengue as per revised NVBDCP guidelines. All other relevant clinical data 
were collected. 
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 Table 1: DENGUE CASE CLASSIFICATION: 
Mild dengue – Fever 
and any two of the 
following- 
Moderate dengue Severe Dengue 
-Nausea, vomiting 
-Rash 
-Aches and pains 
-Leucopenia 
-Positive tourniquet Test 
-
Abdominalpain/Tenderness 
-Persistent vomiting 
-Ascites/ pleural effusion 
-Mucosal bleeding 
-Lethargy, restlessness 
-Liver Enlargement >2 cm 
Laboratory : Increase in 
HCT concurrent with rapid 
decrease in Platelet count 
Severe plasma leakage 
leading to-  
-Shock 
-Fluid accumulation with 
respiratory distress 
-Severe Bleeding  
Severe organ 
Involvement  
-Liver AST or ALT >/= 
1000 
CNS:Impaired 
Consciousness 
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Figure 1: Shows the J Mithra kit used for estimating NS1 Antigen ELISA 
Titres 
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Statistical tools: 
The  data  collected  from  the  patients  were  tabulated  using  Microsoft  
Excel.  The SPSS 23 statistical software was used for data analysis. After 
collecting all the data, all the variables were summarized by descriptive statistics. 
Categorical variables were expressed as frequencies and percentages, and 
Descriptive analysis  was  done  using  chi  square  test  and   p value  of <0.05 was 
considered statistically significant. 
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REVIEW OF LITERATURE 
Dengue infection is one of the widely spreading disease that is present all 
over the world. It is one of the mosquito borne diseases. The causative organism is 
the dengue virus which has 4 different variants. Increased amount of rainfall along 
with abundance of the vector which causes the spread of the disease results in 
epidemics. There are many endemic regions all over the globe where the disease is 
shielded. Wide  distribution of the disease is seen in the Asia Pacific regions which 
exactly coincides with the number of developing countries of the world. The 
number of cases each year is on the rise. The first individual of dengue infection 
was reported in 1789. The first person to report the case was Benjamin who  gave a 
special name to the disease – “the breakbone fever” .The burden of the disease has 
increased  markedly in  the world that in the year 2012 the world health 
organisation classified the disease as “the most important viral disease that is 
transmitted by the mosquitoes” 
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Figure 2: National and subnational evidence consensus on complete absence 
(Green) through to complete presence (Red) of Dengue
 
Dengue viruses originates from animal reservoir. Two distinct DENV 
transmission cycles are recognised (Figure 3) 
 endemic/ epidemic cycle and 
 sylvatic /zoonotic cycle.  
Endemic and epidemic cycles involve the human host and viruses are 
transmitted by A. aegypti, A. Albopictus and other mosquitoes as secondary vectors 
The sylvatic transmission cycle involves monkeys and several different Aedes 
mosquitoes identified in Asia and West Africa. 
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Figure 3: The Two Denv Transmission Cycles 
To clearly understand the real burden of the disease the geographical 
location of the disease should be studied in detail.  The dengue infection has more 
prevalence in the tropical region and many of the areas that are categorized as high 
risk areas come under Asia. 
Temperature of a particular region  plays a major role in the survival of the 
vector which is the major mode of transmission. The socioeconomic status  also 
aids  with the spread of infection 
India was challenged with the first epidemic(not proven virologically but 
only by clinical features) in Chennai and later in Calcutta which was proven 
virologically in the year of 1963. Delhi the most predominant type of dengue virus 
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was of type 2 and 3 but recent trends show type 1 as the most prevalent type in the 
city of Delhi. 
Dengue is mostly spread by  the bite of day time mosquitos  in contrast to 
other disease vectors. Stagnation of clean water is the suitable place for breeding of 
these vectors. 
Individuals once exposed to a mosquito bite the virus  enters the body 
through systemic circulation and lodges in the lymphatics and from there gets 
disseminated to various organ systems of the body. It affects many systems of the 
body but most significant among them are reticuloendothelial system, endothelial 
cell lining the various blood vessels in the body. 
The exact mechanism by which there is varied clinical spectrum of the same 
disease is not understood clearly, but through various studies though not fully 
much more information regarding the pathogenic aspect of the disease has been 
tried to figure out recently. 
Hypothesis had been stated that the imbalance between the inflammatory 
cascade which is triggered by the infection and anti inflammatory pathway is 
responsible for the disease to manifest in various severity levels. Infection leads to 
increased production of inflammatory mediators and increased destruction of  
endothelial cells leading to the destruction of platelets all of leading to  plasma 
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leakage which  holds responsible for most of the clinical manifestations of the 
disease. 
The  clinical spectrum  which ranges from  mild disease to dreadly severe 
form of the disease can be classified broadly into 
NON SEVERE FORM 
 Asymptomatic infection 
 Classical dengue fever 
SEVERE FORM 
 Dengue hemorrhagic fever 
 Dengue shock syndrome 
CLINICAL FEATURES: 
Common symptoms 
 Fever 
 Headache ,arthralgia, malaise, fatigue 
 Generalized maculopapular rash – sometimes associated with itching 
 Facial flushing 
 Conjunctival congestion 
 Gum bleeding 
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Rare features: 
Neurological Manifestations (seen in severe form of the disease): 
 Neck rigidity 
 Pyramidal signs 
 Myoclonus 
 Manic psychosis 
 Hepatic failure leading to encephalopathy 
Gastrointestinal manifestations: 
 Hepatitis  
 Rarely Fulminant hepatic failure 
 Acute pancreatitis 
 Diarrhoea 
 Gall bladder wall edema and thickening 
Cardiovascular manifestation: 
 Av blocks 
 Atrial fibrillation 
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DIAGNOSIS 
Dengue fever: 
Defined as fever whose duration is between two days and one week with 
prodromal symptoms like head ache, malaise,rash etc 
Dengue haemorrhagic fever: 
All of the above criteria with significant haemorhagic manifestations, 
significant drop in platelet count less than 1 lakhs  and with evidence suggestive  of 
severe plasma leakage 
Dengue shock syndrome: 
Includes all the above listed  criteria with features of  circulatory failure 
enough to cause  compensated shock. 
Laboratory diagnosis: 
 Ns1 antigen detection test 
 IgM antibodies that are specific to dengue 
 RT-Polymerase chain reaction 
 Culture of the virus 
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Management: 
  There is no specific antiviral therapy available till now for the disease. 
Management mainly  involves  fluid replacement therapy and management of the 
complications of the illness. 
Mild form of the disease is treated with antipyretics of which aspirin and 
other NSAIDS  are  not preferred and hydration theraphy should be the main stay 
of treatment. 
Periodic monitoring of haematocrit, platelet counts should be done 
Intramuscular injections are  avoided because of the thrombocytopenia which can 
cause significant haematoma. Significant thrombocytopenia of less than one lakh 
should be considered for hospitalization. 
In severe dengue children IV fluids is the main modality  of treatment 
followed by symptomatic management. If there is significant bleeding whole blood  
and Fresh frozen plasma should be the  preferred treatment if clinical suspicion of 
Disseminated intravascular coagulation is suspected. Elective intubation should be 
planned if presentation is of acute respiratory distress syndrome is clinically 
suspected. 
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Dengue is one of the significant vector borne disease,which is spread from 
person to person through  group of mosquitoes –Aedes. 
The DENV is a vector-borne virus transmitted to humans primarily by bites 
from two mosquito species,AedesAegyptior and Aedes albopictus. DENV is a 
single positive-stranded RNA virus belonging to Flavivirus genus of the 
Flaviviridae family. 
  4 major serotypes (DENV1–4) that are antigenically distinct from each 
other. Each DENV serotype is  distinct suggesting that each serotype could be 
considered a separate virus.Dengue  is more common  in the developing  nations. 
Currently there are no particular empirical/prophylactic medications or any other 
vaccinaton available to treat dengue. 
Many similar infection like those of chikungunya and recent epidemic 
causing zika virus also make the diagnosis difficult as it has similar clinical 
manifestations. The best method of preventing the disease occurrence is the vector 
control. 
(2)
 
Dengue outbreak is  difficult to predict  and limited  models  established  for 
predicting the onset of the disease particularly in developing nations,tropical 
countries.
(2)
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Age of people getting affected also varies considerably in various countries. 
In Asian countries pediatric age group tends to get severe disease whereas  
American continents adult age group is the one which is mainly affected.
(2)
 
The severity of Dengue infection  can differ in every individual sometimes 
causing mild less symptomatic disease known as dengue fever which mimics other 
flu like infections to  severe form of  infection called dengue haemorrhagic fever 
and dengue shock syndrome. Both presentations  are the different spectrum of the 
same diseases.  
Dengue can be spread through transfusion of the blood or any of its 
components /organ transplantation which is already contaminated with the virus 
(2)
 
HISTORY OF DENGUE 
Dengue has been known by several names throughout the world, the term 
„dengue‟ has been universally adapted. The origin of the term “dengue”comes 
from the  Swahili word for the disease “ki-dingapepo”. The earliest description of 
an illness called “dengue” can be found in Spanish written records from 1800.(3,4) 
The term “denga”, or “dyenga,”  was coined during the disease  outbreaks in 
East Africa and West Indies during the early 19th century. After the 1828 outbreak 
in Cuba that the Spanish word “dengue” came into general use, which is accepted 
universally now. 
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The earliest historical evidence of dengue like illness were found in China in 
992 A.D. They described the disease as „water poison‟ and  found to be  associated 
with flying insects. The first  epidemic of a disease resembling symptoms of 
dengue was reported in Philadelphia, in 1780. 
In the year 1906, Thomas Lane Bancroft discovered  that the mosquito 
vector Aedesaegypti transmitted dengue. In 1907, Ashburn and Craig proved that 
dengue was caused by a virus.Japanese scientists were first to discover the DENV-
1 in 1943. Subsequently, in 1944, DENV-2 was discovered by Albert Sabin.The 
first reported cases of the severe form of dengue (Dengue Haemorrhagic Fever) 
were seen in Thailand and Philippines during the 1950s. 
The history of dengue outbreaks in India has been recently studied by the 
NVBDCP 
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Figure-4 shows the distribution of dengue cases among the states of India in 
2013 
 
  Mortality in dengue has been reduced significantly even though number of 
cases being reported is increasing considerably every year. 
 
The overall mortality rate of 1.2% in 2007 dropped to 0.25% in 2013, 
compared with the rest of South-East Asia, the number of dengue shock syndrome 
(DSS) cases in India remains low.  
 
A pilot age-stratified, cross sectional dengue prevalence study  was carried 
out at  KEM Hospital Pune which revealed  significantly higher seropositivity of 
58.5% for DENV was found in the urbanized village, compared with 41.2% for the 
rural village.(5) 
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Figure 5 Total dengue cases reported to NVBDCP (left axis) and 
percentage mortality (right axis) in India, 2007–2013 
 
Mortality in paediatric age group was studied by Cherian et al (6)which 
showed a case-fatality rate of 26.3% in a study that included 19 children older than 
1 year in 2012 in the North Arcot district and the adjoining areas of Tamil Nadu 
and Andhra Pradesh.  
Another study, in Mumbai in 2013
(7,8)
 reported three deaths in 38 DHF/DSS 
cases in the paediatric intensive-care unit with a mean age of 4.9 years. 
DENGUE IN TAMILNADU 
During the recent few years the incidence of dengue hemorrhagic fever 
(DHF) has increased markedly in South India. The life span of the vector is 
strongly influenced by temperature and humidity and its survival is best between 
relative humidity of 60– C and 30 . The breeding of A. aegypti fluctuates with 
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unusual rainfall pattern and water storage, as it breeds well in the open containers 
in and around houses. 
In 2010–2012(7,8) outbreaks of dengue/ chikungunya-like illnesses with 
severe clinical manifestations were reported from several districts of Tamil Nadu, 
such as Tirunelveli, Virudunagar, Theni, Madurai, Thiruvallur, Vellore and 
Dharmapuri. 
A study was conducted during three consecutive years(2010-2012) monthly 
data on rainfall, power supply and reported cases of dengue in Tamil Nadu and 
Puducherry. The number of dengue cases was collected from the weekly disease 
alert reports of the Integrated Disease Surveillance Project (IDSP). 
Dengue cases showed a specific pattern of occurrence. Reports showed a 
peak in October followed by gradual decline reaching lowest in February  
Figure 6 shows the monthly dengue cases in Tamilnadu during 2010 to 2012 
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Dengue outbreaks coincided mainly with the northeast monsoon, followed 
by the southwest monsoon with moderate rainfall. With respect to the districts, 
maximum cases were reported from Viluppuram district (226) in 2010, Puducherry 
(152) in 2011 and Puducherry (1600) followed by Tirunelveli (1365) in 2012.  
Deaths were high (40) in 2012, especially from the Tirunelveli district  
EPIDEMIOLOGY 
History of symptoms similar with dengue can be traced back to the China 
Dynasty of 265 Dengue is currently regarded globally as the most important 
mosquito-borne viral disease. A history of dengue epidemics as early as the 420 
AD.
(9)
 
The virus and its vectors have now become widely distributed throughout 
tropical and subtropical regions of the world, particularly over the last half-century. 
Significant geographic distribution has been  associated with rapid rise in incident 
cases, epidemics, and hyperendemicity, leading to the  different and more severe 
forms of dengue.  
Transmission of dengue is now present in WHO region of the world and 
more than 125 countries are known to be dengue endemic.
(9,10)
 
The true impact of dengue globally is tough to determine because of  
inadequate disease surveillance, misdiagnosis, and less number of cases getting 
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reported. Currently available data  grossly underestimates the social, economic, 
and disease burden. Recent  Estimatation  of the global incidence of dengue is 
closer to almost 400 million
(9,10)
 
The global wide distribution of dengue is expected to increase due to factors 
such climate change, globalization, travel, trade, socioeconomics, settlement and 
viral evolution. 
Surveillance and improved reporting of dengue cases is also essential to 
gauge the true global situation as indicated in the objectives of the WHO Global 
Strategy for Dengue Prevention and Control, 2012–2020.(10) 
Three dengue serotypes out of four (DENV 1–3)have been found in Middle 
Eastern countries including Saudi Arabia and Yemen.  DENV-1 strain isolated in 
Saudi Arabia exhibited a high genetic similarity with DENV-1 strain isolated from 
Asian population, suggesting a widespread of the Asian genotype, probably 
through Asian pilgrims 
(11,12)
.Recent publications identified a new serotype 
(DENV-5).
(11)
 
Mosquitoes transmit the virus by feeding on blood of infected persons. At 
first, the virus infects  which replicates in the mid-gut epithelium of the mosquito 
and then spreads to other organs until it reaches the salivary glands after 10–14 
days where it can be inoculated to another person during subsequent blood meal.  
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Vertical transmission of DENV in mosquitoes  from mosquito to larvae has been 
reported by a number of research groups. In India, Angel & Joshi(2008)
(11,12)
 
reported the detection of dengue virus by in-direct fluorescence antibody test 
(IFAT) in laboratory grown mosquitoes originating from larvae collected from 
urban and rural areas  
A similar study was conducted in Brazil by Martins et al. (2012)
(13)
 con-
firmed the isolation of DENV-type 3 in Ae. Albopictus larvae and DENV-type 2 in 
Ae. Aegypti larvae 
(13)
 
Mother-to-infant transmission of dengue virus via cord blood or breast milk 
is not clearly studied.
(14)
 
PATHOGENESIS OF DENGUE 
Pathogenesis of the disease is not clear. Various mechanism has been 
proposed.Large scale research suggests that the pathogenesis of dengue 
haemorrhagic fever and dengue shock syndrome involves both the immune 
response of the host and also the virulence of the virus infecting the host.
(15)
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In vitro and  autopsy suggested that 3 important organs are involved in 
pathogenesis of  severe disease. Endothelialcells which form the inner  liningof the 
blood vessels,the liver and the immune system. 
Understanding the various changes occurring in the above three systems 
during the course of illness the overall pathogenesis is known clearly. 
Once a host is infected with the virus through the bite of the infected 
mosquite the dengue virus gets into the blood and systemic circulation . 
Langerhan cells and keratinocytes are infected  initially from which it is 
transmitted to cells like monocyte and macrophages 
This occurs once the infected langerhan cells enter the lymph nodes in which 
monocytes and macrophages are concentrated. Through  this mechanism the 
infection is spread extensively and  affecting various cells including several organ 
systems like those in  spleen ,bone marrow and lymphatic system. 
During reinfection with other type of dengue virus the IgG formed during 
the previous infection causes a complex with the current infection causing virus 
which is engulfed by the mononuclear cells. 
Mononuclear cells get destroyed by apoptic pathways, which  releases  
excessive inflammatory mediators. 
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Load of viraemia determines the extent of inflammatory response of the 
body.
(15)
 
Autopsy studies have demonstrated  the presence of dengue virus at various 
organ systems like skin,liver,spleen,kidney,brain etc.
(16)
 
Animal studies suggests that liver is the most commonly involved organ 
which also is proven with the occurrence of dengue hepatitis in humans((16) 
As the  endothelial cell layer gets involved the microvascular bed which is 
near the dermal papillae is affected mainly. 
Studies have also suggested the significant involvement of endothelium in 
the pulmonary blood vessels.  Functional  damage is more common  than 
anatomical damage. 
Exact mechanism by which endothelial layer  involvement varies in different 
organ systems is not clear. 
The involvement of  endothelial layer  and increased permeability  is the 
main pathology involved in dengue shock. 
Due to the  increased vascular leakage occurring secondary to the increased 
permeability which is more marked in the abdominal and pulmonary vessels there 
is fluid collection in pleural and peritoneal cavities. 
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One of the important non-structural protein 1 (NS1) of the dengue virus has more 
affinity to the endothelial layer lining the lungs and liver and it is important in the  
diagnosis  of the disease.
(16,17)
 
Hypothesis says that certain strains of the virus cause more severe disease 
due to the virulence factor of the virus which is different for each of the 4 subtypes 
of the viruses 
After various studies it has been suggested that high incidence of the severe 
form of the disease i.e dengue shock syndrome/dengue haemorrhagic fever occur 
more commonly occur in denv 1.
(18)
 followed by dengue virus type 2 and dengue 
virus type 3. 
  During reinfection the disease severity is linearly associated with the time 
interval between the primary infection and the reinfection.And  if  an individual  
during  secondary infection has acquired a different virus type  from the primary 
infection then  the risk of the individual getting severe infection is much higher. 
Virulence of the virus varies with different geographical location. 
Severe disease in primary infection is not that common compared to the 
secondary infection. 
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Complement pathway  of the body also plays a role in the pathogenesis of 
the disease which  causes increased levels of components like C3a ,C5a levels in 
individuals with DSS/DHF.
(19)
 
Non structural protein of the dengue virus triggers formation of antibodies 
which binds  which  causes activation of the complement system and various other 
pro inflammatory mediators. 
The antibody of IgG class is also component which causes excessive 
inflammatory reaction in the secondary dengue. 
NS1 Proteins show some increased response of cross reaction to  the 
endothelial lining of blood vessels and platelets  which  causes  increased 
production of nitric oxide in these cells and accelerated apoptosis of these cells and 
also increased plasma leakage via these cells 
(20,21)
 
Components like IL6,IL8 are also enhanced due to the interaction of the 
antibodies with various cells of the body. 
       Severity of the disease can vary for each person due to the various difference 
between each host. The difference can be at a genetic level and also due to the 
difference in immunity. 
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Certain HLA class individuals are more prone to develop severe form of the 
disease like dengue shock syndrome and dengue haemmorhagic fever.Certain 
changes in genetic levels causes difference in formation of inflammatory mediators 
like polymorphism of TNF α,TGFβ leads to low threshold for formation of dengue 
shock syndrome/dengue haemorhagic fever. 
Polymorphism in  transporter protein associated with human platelet antigen 
also causes individuals to be more prone to develop dengue haemorrhagic fever 
(21)
 
Some of these inflammatory mediators are also being evaluated for their 
correlation with dengue severity and duration 
  Chaiyaratana et al 
(22)
 for evaluating serum ferritin levels as a predictor of 
severe dengue. 
This study was done among 100 children in Thailand 
Ferritin level value of 1200 to calculate both the sensitivity and specificity 
and suggested that children who had  ferritin levels above this cutoff value had 
more chance of developing the severe form of the disease i.e DHF. 
 Study suggested that Ferrtin  is a acute phase reactant can be used to predict 
the severity of the disease 
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Lowel et al 
(23)
 perfomed a study comprising  of  54 children concluded the 
correlation of severity in relation to interferon gamma levels and interleukin 10  
and interleukin 2 levels.  
Third space fluid collection and the severity of the thrombocytopenia were 
also correlated 
Daisy vanitha et al 
(24)
 has suggested that the severity of the disease  was 
directly proportionate to the urinary histamine levels  due to the significant rise in 
the mast cell activity. 
Hemagglutination (HI)test is  recommended by World health organization 
but it has certain disadvantages  because of the tough methodology  and it requires 
drawing of blood sample twice at a particular time interval.  Cross reactivity with 
other viruses has been proved because of HI.  Study done by Severine Matheus et 
al 
(26,27)
 formulated  ELISA which was based on  the theory that changes in 
Immunoglobulin G during the acute phase of the disease was formulated. 
  Desouza et al 
(28,29)
 suggested a newer ELISA screening for IgG  which 
distinguishes between secondary and primary disease can be done by screening for 
avid IgG. 
  Study done by Matheus et al 
(30)
 showed that affinity for IgG was greater in 
secondary dengue compared to the primary infection and the  sensitivity/specificity  
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derived from the study showed that it was an effective screening tool to distinguish 
between the two forms(primary/secondary).The efficiency of the test  was proved 
more effficient during the convaselcent phase  compared to the  early febrile phase. 
Advantage of this test showed  that it can be performed only once during the later 
phases whereas the former showed testing twice at two different intervals. 
 
Severe dengue infection is characterized by excessive activation of the 
immune mediators. Lipopolysaccharide was found to be increased markedly in  
people with dengue infection and  studies  suggested that the serum levels of LPS 
had a good correlation with the severity of the disease. 
Cornelia et al 
(31)
  suggested that the microbial translocation was associated 
with  immune system activation which happens in severe dengue.This study was 
conducted in Brazil where levels of LPS, IgM,IgG and cd14 and many other 
cytokines were measured.Other markers for microbial translocation like RANTES, 
Interleukin 6 etc were also measured and it revealed that  severity of the disease 
was statistically  correlating with the levels of the above markers. 
One  study was conducted by kala jesi et al 
(32)
 in which the practical 
estimation  of detection of viral RNA in tissues of the infected individuals was 
demonstrated. They showed the presence of the viral RNA in the macrophages 
present in spleen and also the monocytes of the peripheral circulation. 
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Methodology used to detect the viral RNA was through Immuno histochemistry 
and in situ hybridization. The following figure gives us the tissues in which viral 
RNA was detected 
 
Viral antigens and RNA detection in various organ systems are shown in the 
following pictures (Fig 7) 
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One of the fatal complication of severe dengue is the bleeding manifestation. 
Wills et al 
(33)
 conducted a study  in dengue infected patients of  pediatric age 
group in Vietnam   Study was conducted in one sixty seven subjects who had the 
severe dengue. 
After  continuous and daily monitoring it was  found out that Prothrombin 
time and the commonly used activated partial thromboplastin time had no 
significant abnormalities and had a mild prolongation of  these parameters and 
level of fibrinogen measured was significantly  low.  
Protein C and protein S, the naturally occurring anticoagulants were 
significantly reduced. 
Similar findings were also found in another natural anticoagulant i.e 
antithrombin. Plasminogen activator inhibitor showed marked increase in 
circulating levels and had significant  correlation with the clinical severity of the 
disease 
Study done by  Eric et al 
(34)
 included  fifty subjects and the total subjects 
were divided into two based on the final outcome.All the subjects  were children 
who had DHF and there various coagulation parameters were monitored and 
compared to each other.A  total number of  13 subjects died during the study 
period.   
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Both the coagulation and anticoagulation cascade showed increased activity 
in the acute phase of the disease which showed altered thrombin  and 
antithrombins level. Among the two groups the  children who survived  showed an  
established compensated acceleration of anticoagulant cascade by means of 
increased natural  anticoagulants like protein C and  S and other factors that 
activate the fibrinolytic pathway activation. In the mortality group the this 
compensation did not occur efficiently and these children had a final effect which 
had more  procoagulant nature resulting in more severe multiorgan system 
involvement. 
The study group had   increased levels of inhibitors of plasminogen. Results 
of the study  suggested that  procoagulant markers and the ratio of anti to 
procoagulant markers can be used as a marker which can guide treatment and 
grade severity. 
Thrombocytopenia  is  the hall mark and very common laboratory finding in 
the dengue fever even in mild dengue. 
Mechanism which has been proposed by various studies is that there is 
increase in the adhesion of platelets to the wall of the vessels due to certain 
changes in the endothelial layer. 
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In  a study conducted by Krishnamurthi et al 
(35,36)
 the above stated 
mechanism was tried to explained. 
The rise in viral load and tendency of increased adhesion  had a greater 
correlation. It was also found that platelets which showed increased adhesion was  
activated  following rise in the level of components like selectin, adhesion 
molecule etc whose function is to aggregate the  function of adhesion of 
thrombocytes.Other mechanism like raised inflammatory reactions that occurs in 
dengue also causes significant  decrease in functional activity of the platelets and 
also more destruction of the circulating thrombocytes stating that the cause of 
thrombocytopenia in dengue is multifactorial. 
Liver is one of the common organ involved in dengue.The extent of damage 
that occurs in the organ is shown by the derangement in the liver enzymes.  Liver 
involvement is transient and the  liver function return back to normal after recovery 
from the viral illness the markers of liver damage like ALT,AST has shown to  
determine severity and adopted  in the WHO 2009 classification of dengue. 
The host defence mechanism and other various difference between 
individuals also change the course of the disease to varied extent. Latest studies 
showed that the gentic makeup of a particular individual also plays  significance in 
the pathogenesis.  Research has demonstrated  the importance of few genes 
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“LOC286087, SMAD5, PSPH” etc can lead to that particular individual being 
more prone to develop the severe form of the disease 
 
   In the below diagram various available biomarkers that can be used in 
predicting and assessing the severity of the dengue infection
 (34)  
 
 
 38 
STRUCTURAL IMPORTANCE OF DENGUE VIRUS 
Dengue virus is a positive stranded, encapsulated RNA virus 11kb in size 
and has a single Open Reading Frame (ORF) encoding for a single polypeptide 
which is further processed into three structural proteins,(4) that is the Capsid (C), 
Membrane (M), and Envelope (E) proteins, and seven non-structural (NS1) 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) 
  Seven nonstructural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5. These nonstructural proteins play roles in viral replication and assembly. 
 
Figure 8 Dengue virus structure 
The dengue virus has a roughly spherical shape. Inside the virus is the 
nucleocapsid, which is made of the viral genome and C proteins. The nucleocapsid 
is surrounded by a membrane called the viral envelope, a lipid bilayer that is taken 
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from the host. Embedded in the viral envelope are E and M proteins that span 
through the lipid bilayer. These proteins form a protective outer layer that controls 
the entry of the virus into human cells. 
The structure of the dengue virus is roughly spherical, with a diameter of 
approximately 50 nm (1 nm is one millionth of 1 mm) . The core of the virus is the 
nucleocapsid, a structure that is made of the viral genome along with C proteins. 
The nucleocapsid is surrounded by a membrane called the viral envelope, a lipid 
bilayer that is taken from the host. Embedded in the viral envelope are 180 copies 
of the E and M proteins that span through the lipid bilayer. These proteins form a 
protective outer layer that controls the entry of the virus into human cells. 
Dengue Virus Replication and Infectious Cycle 
The dengue viral replication process begins when the virus attaches to a 
human skin cell . After this attachment, the skin cell's membrane folds around the 
virus and forms a pouch that seals around the virus particle. This pouch is called an 
endosome. A cell normally uses endosomes to take in large molecules and particles 
from outside the cell for nourishment. By hijacking this normal cell process, the 
dengue virus is able to enter a host cell. 
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Figure 9: Dengue virus replication 
The dengue virus attaches to the surface of a host cell and enters the cell by 
a process called endocytosis. Once deep inside the cell, the virus fuses with the 
endosomal membrane and is released into the cytoplasm. The virus particle comes 
apart, releasing the viral genome. The viral RNA (vRNA) is translated into a single 
polypeptide that is cut into ten proteins, and the viral genome is replicated. Virus 
assembly occurs on the surface of the endoplasmic reticulum (ER) when the 
structural proteins and newly synthesized RNA bud out from the ER. The 
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immature viral particles are transported through the trans-Golgi network (TGN), 
where they mature and convert to their infectious form. The mature viruses are 
then released from the cell and can go on to infect other cells.Once the virus has 
entered a host cell, the virus penetrates deeper into the cell while still inside the 
endosome.  
1. The endosome must be deep inside the cell where the environment is acidic. 
2. The endosomal membrane must gain a negative charge. 
These two conditions allow the virus envelope to fuse with the endosomal 
membrane, and that process releases the dengue nucleocapsid into the cytoplasm of 
the cell. 
Once it is released into the cell cytoplasm, the nucleocapsid opens to uncoat 
the viral genome. This process releases the viral RNA into the cytoplasm. The viral 
RNA then hijacks the host cell's machinery to replicate itself. The virus uses 
ribosomes on the host's rough endoplasmic reticulum (ER) to translate the viral 
RNA and produce the viral polypeptide. This polypeptide is then cut to form the 
ten dengue proteins. 
The newly synthesized viral RNA is enclosed in the C proteins, forming a 
nucleocapid. The nucleocapsid enters the rough ER and is enveloped in the ER 
membrane and surrounded by the M and E proteins. This step adds the viral 
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envelope and protective outer layer. The immature viruses travel through the Golgi 
apparatus complex, where the viruses mature and convert into their infectious 
form. The mature dengue viruses are then released from the cell and can go on to 
infect other cells. 
There are four serotypes of dengue virus (DEN1-4) and the recovery of 
infection  differs from one serotype can confer life-long protection against that 
serotype but not against the other three serotypes.  
Severe dengue infection usually occurs after a second infection with a 
different serotype, which is due to immune-mediated antibody-dependent 
enhancement (ADE). 
The revised World Health Organization dengue fever guidelines 2011
(25)
 
have emphasized the need for early diagnosis and treatment to reduce the mortality 
due to severe dengue infection. 
  The classical methods of confirmation of diagnosis are virus isolation, 
serotype identification, antibody detection tests (IgM and IgG MAC-ELISA), 
haemagglutination inhibition or neutralization tests but all these tests are time 
consuming and do not help in the confirmation of diagnosis at an early stage of 
illness.  
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The serological diagnosis by IgM/IgG MAC ELISA has been the most 
common method of confirmation of dengue fever and has sensitivity and 
specificity of approximately 90% and 98%, respectively but the problem is that it 
is only detected in the convalescent phase of illness.  
With the advent of NS1 antigen assay, there has been marked  rise in early 
diagnosis of dengue fever as it develops during the acute phase of illness (0-7 
days) and is emerging as a suitable option for dengue diagnosis in the first week of 
illness with high sensitivity and specificity.
(34)
 
 NS 1 antigen assays show consistently high sensitivity (81%) (32)during 
first 6 days of illness and is more  cost effective. Dengue NS1 antigen is positive 
for a longer duration in primry dengue infections than in secondary cases. 
The use of NS1 rapid diagnostic tests significantly contributes in 
withholding unnecessary use  of antibiotics in patients 
(34,35)
. NS1 antigen positivity 
can be associated with an increased risk for developing dengue hemorrhgic fever 
or dengue shock syndrome particularly when it is positive beyond the fifth day of 
illness  which can be used as a warning sign for the severity of dengue fever
(34,35)
. 
There are multiple mechanisms by which increased NS1 antigenemia can 
contribute to severe dengue fever. 
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NS1  antigen is a 50kDA non structural protein that  carries lipids in its 
secretory form it can contribute to the pathogenesis of severe dengue as 
lipoproteins are involved in coagulation pathways and can produce vascular 
inflammation. 
NS1 antigen stimulates production of IL 10 and  annexin V which are 
cytokines having an immunosuppressive effect in a dose dependent manner 
therefore increased levels of circulating NS1 levels can have an indirect 
immunosuppressive effect contributing to an increased severity of the disease by 
causing apoptosis of DENV speific T cells
(36)
 
The endothelial glycocalyx layer is a network of proteoglycans and 
glycoproteins which lines the vascular endothelium and plays an important role in 
maintaining the endothelial barrier function.It contains sialic acid and heparin 
sulphate. 
 Ns1 antigen expresses sialase and heparanase enzymes which causes 
disruption of endothelial glycocalyx layer and induces vascular hypermaleabilty 
particularly in microvasculature of lungs leading to capillary leakage and fluid 
accumulation in third space (pleura) in severe dengue
(36,37,38)
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Ns1 antigen has also been associated witth stimulation of Macrophage 
Inhibitory Factor which causes autophagy of endothelial cells leading to vascular 
leakage and manifestation of severe dengue fever 
(39,40)
 
Paranavitane et al 
(41)
 evaluated the use of the NS1 antigen test as a marker 
of severe dengue infection.  NS1 antigen positivity especially done within day 5 of 
illness, was associated with a higher risk of developing severe dengue (odds ratio 
3.0).  
In order to evaluate the usefulness of the NS1 antigen positivity as a marker 
of severe clinical disease 313 children with an acute dengue infection was included 
in the study and  there was a significant correlation with liver transaminases.  
CLINICALMANIFESTATIONS 
Clinical manifestations of dengue disease  can lead to a wide range of 
clinical manifestations, from mild fever to plasma leakage and the potentially fatal 
dengue shock syndrome. 
The clinical  manifestations of dengue in infants differ, with a greater 
incidence of plasma leakage and shock compared with dengue in older children. 
Dengue disease was originally classified by the WHO into dengue fever, 
dengue hemorrhagic fever and dengue shock syndrome. 
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 2011 WHO guidelines classification includes Dengue like illness, Dengue with 
warning signs and Severe Dengue
(25)
 
Dengue with warning signs 
The early signs of the disease are non-specific.  
According to the WHO classification (2009) Dengue fever is characterized 
by febrile episode (≥40 °C for 2–7 days)  associated with rash, nausea, vomiting, 
and headache.  
Although the disease affects people of all ages from infancy through to 
adulthood  Studies have  showed that children tend to tolerate this phase of illness 
better than adults 
The combination of above mentioned symptoms and other symptoms, such 
as abdominal pain, mucosal bleed, and lethargy and restlessness can be seen 3–7 
days later. 
Lab investigations of mild dengue fever cases usually shows abnormal 
leukocyte counts and moderate elevation of the hepatic amino transferases. 
  The above symptoms are warning signs to progress for severe dengue if 
correct management is not done.  
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Clinical monitoring and surveillance are necessary  to prevent vascular 
leakage, especially in an endemic areas. 
Severe dengue 
This form of dengue infection can be attributed to any of the four known 
serotypes DENV 1–4. 
About 5–10 % of patients progress to develop a severe Dengue 
haemorrhagic fever/ Dengue shock syndrome which can be fatal. 
This form develops at a late stage of Dengue fever where  affected 
individuals may go through defervescence phase followed by sudden drop of 
body‟s temperature. 
  This phase is also identified by severe bleeding, particularly bleeding from 
the gastrointestinal tract (black, tarry stool),and thrombocytopenia (<50,000/mm3), 
which may affect up to 50 % of the affected people . 
Interestingly, here was an observed negative correlation between the severity 
of DHF and the level of platelets in the blood.
 (39)
 
The exact mechanism of this correlation is not clear. The drop of platelet 
counts and the loss of their functionality lead to a vascular fragility increasing the 
risk of plasma leakage. 
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CLINICAL COURSE OF DENGUE  
WHO divides the course of illness in to three phases -the febrile, critical and 
recovery phase. Children in the febrile phase typically develop fever, headache 
with or without retro orbital pain, myalgia, arthralgia, and a maculopapular to 
petechial rash. 
Although children usually suffer from high fever, they are generally less 
symptomatic during this phase of the illness. 
Mild hemorrhagic manifestations like petechiae and mucosal membrane 
bleeding (e.g. nose and gums) may be seen. This phase lasts for 3-7 days, after 
which most children recover without complications. In a small proportion of 
children a systemic vascular leak syndrome becomes apparent around the time of 
defervescence. 
The critical phase is characterized by a progressive leukopenia with a 
declining platelet count, hemorrhagic manifestations, pleural effusions, ascites and 
hypoproteinemia. 
Shock occurs when a critical volume of plasma is lost through leakage. 
Vascular leakage and shock are more frequent and more severe in children than in 
adults while bleeding manifestations and organ involvement are more common in 
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adults. Clinically significant bleeding in the critical phase of dengue infection in 
children usually occurs only in association with profound and prolonged shock. 
The altered vascular permeability reverts spontaneously to a normal level 
after approximately 48-72 hours during the recovery phase. 
  General well-being improves, appetite returns, gastrointestinal symptoms 
resolves and children start to diurse with normal haemodynamics. 
ANTIBODY- RESPONSE IN DENGUE 
The antibody response against dengue virus infection is mainly triggered by 
the precursor membrane (pre -M) and envelope (E) structural proteins and the non 
-structural protein 1 (NS1) 
(40-42)
 
Dengue virions bind to cell surface receptors and virions are internalized by 
endocytosis.  
After release  of viral RNA into the cytoplasm of the host cell, the viral 
genomic RNA is translated to produce viral proteins which assemble into immature 
virions within the lumen. 
In the immature virions, the pre -M protein forms a heterodimer with the E 
protein. Subsequently, this heterodimer is cleaved which leads to the formation of 
mature virions, which are secreted from the cell.  
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In the mature virions, the M protein is completely hidden by the E protein 
dimers making it inaccessible to antibody binding. However, incomplete cleavage 
appears to be common, yielding immature particles that can be bound by pre -M 
protein-specific antibodies. Mature and immature virions induce antibody 
responses to the E protein
(40-42)
 
SIGNIFICANCE OF NS1 ANTIGEN 
The NS1 protein is a glycoprotein that is produced in infected cells, but is 
not incorporated into the virion. In a child with dengue, NS1 is situated on the 
plasma membranes of cells and in the circulation.  
Antibodies interact with NS1 to cause complement -dependent lysis of virus-
infected cells.  
Further NS1 - specific antibodies probably contribute  to antibody-dependent 
cellular cyto toxicity. 
  Neutralization of infection by dengue virus -specific antibodies can occur 
through several different mechanisms, including inhibition of binding to cell 
surface receptors or post -binding inhibition of viral fusion with endosomes. 
Neutralizing antibodies directed against the E protein are highly serotype 
cross-reactive.  
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The tropism of dengue virus for monocytes and macrophages, which both 
express receptors for immunoglobulins, leads to the entry of dengue virus into host 
cells,This phenomen is called „antibody- dependent enhancement of infection‟.  
This occurs because virus-antibody complexes infect host monocytes more 
efficiently than free virus particles. 
Anti-body dependent enhancement of infection can be mediated by E protein 
-specific or pre-M antibodies and occurs when antibody concentration is low so 
that the number of antibody molecules bound per virion is below the threshold 
necessary for neutralization of the virus. In genetically predisposed individuals, 
subsequent infection of monocytes by virus -antibody complexes can also 
influence cellular immune responses. 
NS1 ELISA TESTING 
Enzyme-Linked Immunosorbent Assays (ELISA) directed against Non-
Structural glycoproteins (NS1 Antigen) have demonstrated very high 
concentrations in the sera of dengue virus infected patients during the early clinical 
phase of the disease and represents a new approach to the diagnosis of acute 
dengue infection. 
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  NS1 antigen assay, there has shown marked rise in early diagnosis of dengue 
fever during the first week of illness especially during epidemics but its role as an 
early predictor of severe dengue infection is not very clear. 
The major diagnostic methods currently available are viral culture, viral 
RNA detection by reverse transcriptase PCR (RT-PCR) and serological tests such 
as an immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay 
(MAC-ELISA). However, early dengue diagnosis still remains a problem, as all 
these assays have their own draw backs. The first two assays have restricted scope 
as a routine diagnostic procedure 
  Viral isolation by cell culture and subsequent detection by immune 
fluorescence, though the gold standard cannot be used as a routine diagnostic 
procedure due to its low sensitivity and time consumption. The requirement of a 
highly trained staff, the need of a sophisticated equipment as well as the cost factor 
associated with molecular methods has limited its application as a routine 
diagnostic assay.  
The requirement of paired sera at acute and convalescent phase, which 
improves the accuracy of the diagnosis, further delays the treatment. NS1 (non-
structural protein 1) is a highly conserved glycoprotein that is essential for the 
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viability of DV and is produced both in membrane-associated and secretory forms 
by the virus. 
(43,44,45,46)
 
Enzyme-linked immunosorbent assays (ELISA) directed against NS1 
antigen (NS1 Ag) have demonstrated its presence at high concentrations in the sera 
of DV infected patients during the early clinical phase of the disease. 
SIMILAR STUDIES DEMONSTRATING NS1 ANTIGEN TESTING 
Study by Kassim et al 
(47,48)
 showed the usefulness of the dengue NS1 
antigen test was evaluated as a routine, rapid diagnostic test for dengue virus 
infection.  The results reveal the detection rate of dengue virus infection was 
similar for PCR and dengue antibody (65.9%) and for NS1 antigen and dengue 
antibody (62.0%) combinations.  
Dengue NS1 antigen test can be used to complement the current antibody 
test used in peripheral laboratories. Thus, the combination of the NS1 antigen and 
antibody tests could increase the diagnostic efficiency for early diagnosis of 
dengue infection. 
 Varen et al 
(49)
 suggested NS1 ELISA testing showed  sensitivity varies 
depending on the serological status of the patient, date of specimen collection and 
serotype of the infecting virus, its use for accurate diagnosis of dengue infection 
should be considered by clinicians especially early in infection. 
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A total of 208 sera from patients suspected of having dengue virus infection 
were collected and tested for dengue antibody, dengue genome and dengue NS1 
antigen. Dengue antibody test, dengue PCR test and dengue antigen test were able 
to detect dengue virus infection from Days 1 to 8 in 72.8, 52.8 and 44.0% of 
samples, respectively. 
Of the 208 sera tested, 69.2% (144/208) of the acute sera were positive for 
dengue virus infection based on IgM antibody, IgG antibody, NS1 antigen and 
PCR tests. Thirty-two point two percent of the samples (67/208) were found 
positive for dengue NS1 antigen, 38.5% (80/208) were PCR positive, 40.9% 
(85/208) were IgM positive and 36.1% (75/208) were IgG positive for dengue 
virus 
Borez et al conducted
(50)
 a study  in 329 patients with age mean group was 
6.8 found there is significant increased in platelet count after complete treatment . 
In severe cases there was done platelet transfusion (18.22 % cases ) . 14.92 % 
cases were admitted in ICU. Diagnosis of dengue by NS1 antigen and IgM Elisa in 
tertiary care found statistically significant (P< 0.01) 
Similar study done by Bhazuki et al 
(51)
 stated that NS1 ELISA quantified 
during the early febrile phase and higher sera concenterations were observed in 
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children with  during the early phase of illness was statistically significant in 
children developing severe dengue. P value observed was <0.05 
Thomas et al 
(52)
 conducted a study in a tertiary hospital during an outbreak 
showed that dengue NS1 ELISA titres  were found to be high in children during 
the febrile phase. This study was found to have clinical correlate with severe 
dengue fever and children were triaged and there was a significant reduction in the 
mortality. 
Study conducted by Alcon et al 
(53) 
showed that high circulating levels of 
NS1 ELISA assay showed a clinical correlation with secondary dengue fever 
where higher NS1 levels clinically correlated with increasing titres of IgG 
antibodies done during convasalcent phase. P value was <0.05 and the the study 
was done in a controlled population who required critical care monitoring. 
Jeanne et al 
(54)
  suggested  a quantitative NS1 ELISA Assay  which showed 
a cut off level  of six hundred ng/ml could be used as cutoff level for it so that any 
individual whose value is more than this within three days of onset of symptoms  
can be more prone to develop the severe form of the disease especially dengue 
haemorrhagic fever. 
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Maria et al 
(55)
  showed that high levels of NS1 antigen titres with a cut off of 
> 50 ng/ml done during first three days of illness was found statistical correlation 
with children with dengue fever in Indonesian population 
Duan et al
(56)
 showed that high levels of NS1 Antigen was also correlated 
with  severe thrombocytopenia and increasing titre values were found to have 
statistical correlation with shock.
(54)
 
Prospective study done by Dussart et al 
(57)
 showed that high circulating 
levels of NS1 antigen was found to have statistical correlation with children of 
dengue haemorrhagic fever and the p value was < 0.03 
The method using the NS1Ag is one of the very effective method for 
diagnosis and it has a very good sensitivity level. NS1Antigen is  specific to 
dengue infection , and can detect dengue virus effectively irrespective of the type it 
belongs. The relative easy availability easy method by which it is performed along 
with the time factor makes it a very valuable tool for the early diagnosis of the 
disease and can be used as an early marker during epidemics to classify severe 
cases. 
When it comes to the treatment of patients who are infected with any type of 
dengue virus care must be taken to closely monitor the patients who are known to 
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have secondary dengue because patients with secondary infection  are vulnerable 
to severe  infections. 
MANAGEMENT IN DENGUE 
Fluid therapy which restores the third space fluid loss is the most important 
aspect of treatment. Correct diagnosis with  scheduled timing of treatment the 
burden of the disease can be lowered. Some of the import guidelines proposed are  
  Those patients starting to develop the symptoms of dengue but not 
with any of the warning sign proposed by WHO are to be treated with 
adequate oral fluids and antipyretic agents and if symptoms are more 
can also be given adequate analgesics. 
 Next if the patient has all the above mentioned features but has 
developed one or more of the warning signs proposed by WHO then 
the intensity of oral rehydration therapy should be much more intense 
and vigorous along with other symptomatic management mentioned 
above 
 If patient has above mentioned features and increase in “PACKED 
CELL VOLUME-PCV” of less than ten percentage of the previous 
base value and presence or absence of low platelet count which in this 
case is between fifty thousand and one lakh patient should be kept 
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under  supervision and other symptomatic measures suggested above 
should be done 
 PCV which has been increased above the level of ten percentage to 
the previous normal value or base value and if thw patient has 
presence or absence of the WHO proposed warning signs then the 
patient should be hydrated well using IV fluids (crystalloids are 
preferred) and monitoring of the PCV should be done 
 If a patient developes shock then care should be given with aggressive 
colloid infusion and other iv fluids 
 If a patient comes under the category of DHF then patient should be 
given whole blood or FFP based on the amount of bleeding. 
Prevention of the disease is very important since it poses a great threat to the 
community itself rather than a individual or a group of people. Control or 
preventing the vector which is the major mode responsible for the disease spread is 
the centre of goal in preventing dengue. Some of the methods are 
 Using chemicals to prevent vector development 
 Reduction of stagnation of water 
 Adequate drainage system 
 Mosquito traps 
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 Preventing the bite using chemical mosquito repellants 
 Social awareness about the disease 
 Training the medical care system to contain the disease spread during 
epidemics  
 
NEWER MODALITIES IN DENGUE PREVENTION 
Efficient way of preventing dengue infection is Vaccination.  The important 
fact which warrants the necessity for need of a efficient vaccination is that first 
infection with dengue does not offer permanent immunity and the risk of 
subsequent infection  is also possible. Subsequent reinfection with the dengue virus 
whith different serotype results in more chance of  developing  severe form of the 
disease. This is explained by the inflammatory reaction associated with dengue 
which plays a important role in the pathogenesis of the disease is increased in 
subsequent infection. 
Developing a vaccine for dengue is difficult because a  vaccine should be 
developed for all of the four existing subtypes. Stephen J 
(58)
 has described the 
various aspects of the vaccination and some of the important trials that is taking 
place in the field  
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RESULTS 
Our study was conducted at Pediatrics department PSG Hospitals, 
Coimbatore which is a tertiary care hospital. Our study period was betweenJanuary 
2016 to May 2017. In a total of 690 children who were serologically positive for 
Dengue fever, 270 children were included in the study and 250 children were 
finally included for study analysis and  20 children were excluded because of 
logistic reasons and comorbidities. Results were tabulated and comparisons were 
done. 
Table 2 
Distribution of study population according to age group 
Age group Number Percentage 
< 5 years 120 48 
6-10 years 71 28.4 
11-15 years 40 16 
>15 years 19 7.6 
Total 250 100 
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Figure 10 - Distribution of study population according to age group 
 
Table 2 and Figure 10 shows  the total number of  children included in the 
study. Out of 250 children 120 children (48%) were less than 5 years, 71 children 
(28.4%) were between 6 to 10 years, 40 children(16%) were between 11 to 15 
years and 19 children (7.6%) were above  15 years. 
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Table 3:  
Sex distribution 
Study group Male Female 
Number 133 117 
Percentage 53% 47% 
 
 
Fig 11 shows the sex distribution of the study group of which 53% were 
male children and 47% were female children 
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Table 4 
Distribution of study population according to admission status 
Admission Number Percentage 
Admitted 224 89.6 
Not admitted 26 10.4 
Total 250 100 
 
Figure 12 Distribution of study population according to admission status 
 
Table 4 and figure 12 shows  the admission status of study population. Out 
of 250 children 224 children were admitted (90%) and 24 children(10%) were 
treated as outpatients 
90%
10%
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Table 5 
NS1 Antigen positivity related to day of illness 
Day  of illness Number Percentage 
<3 days 158 63.2 
4 to 5 days 92 36.8 
Total 250 100 
 
Figure 13- NS1 Antigen positivity related to day of illness 
 
Table 5 and fig 13 shows that NS1 titre values were found to be positive in 
158(63.2%) children when NS1 antigen Assay was done in less than 3 days of 
illness.  NS1 antigen was positive in 92 children (36.8%) when done on 4 to 5 days 
of illness. 
63%
37%
<3 days >3 days
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Table 6 
Distribution of study population according to NS1 titre levels 
NS1 levels Number Percentage 
< 9 81 32.4 
9-11 74 29.4 
>11 95 38 
Total 250 100 
 
Figure 14 Distribution of study population according to NS1 titre levels 
 
Table 6 and Fig 14 showed the titre values of the study population. Titre values of 
<9 were seen in 81(32.4%) children, titre values of 9 to 11(29.4%) were seen in 74 
children and titre values of >11(38%) were seen in 95(38%)of the children. 
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Table 7 
Association between age group and NS1 titre levels in the study population 
Age group Titres<9 percentage 
< 5 years 43 35.8 
6 - 10 years 23 32.4 
11 - 15 years 8 20 
> 15 years 7 36.8 
 
Figure 15 Association between age group and NS1 titre levels in the study 
population 
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Table 7 and fig 15 shows the association between age group and and NS1 
titres. In age group of less than 5 years, titre values of less than9 was seen in 43 
children(35.8%)and in age group of 6 to 10 years titre values of  less than 9 was 
seen in 23 children( 32.4%). In children with age group of 11 to 15 years titre 
values of <9 was seen in 8 (20%) children. Children with age group of 11 to 15 
years NS1 antigen titre values of <9 was seen in 7(36.8%) children 
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Table 8 Association between age group and NS1 titre levels in the study 
population 
Age group Titres 9 to 11 percentage 
< 5 years 32 26.7 
6 - 10 years 26 36.6 
11 - 15 years 12 30 
> 15 years 4 21.1 
 
Figure 16 Association between age group and NS1 titre levels in the 
study population 
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 Table 8 and fig 16 showed the association between age group and NS1 titres, 
In the age group of less than 5 years titre values of 9 to 11  was seen in 
32(26.7%)of the children, in the age group of 6 to 10 years titre values of 9 to 11 
was seen in 26(36.6%) of the children. In the age group of 11 to 15 years titre 
values of 9 to 11 was seen in12(30%) of the children, in age group of > 15 years 
titre values of 9 to 11 was seen in 4 (21.1%) children  
  
 70 
Table 9 Association between age group and NS1 titre levels in the study 
population 
Age group Titres> 11 percentage 
< 5 years 45 37.5% 
6 - 10 years 22 31% 
11 - 15 years 20 50% 
> 15 years 8 42.1% 
 
Figure 18 Association between age group and NS1 titre levels in the study 
population 
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Table 9 and Fig 18 shows the association between age group and NS1 titre 
levels. In the age group of children <5 years titre values of> 11 was seen in 
45(37.5%) children, in children with age group of 6 to 10 years titre values > 11 
was seen in 22(31%) of the children. In age group of children between 11 to 15 
years titre values of > 11 was seen in 20(50%) of the children. In age group of 
children > 15 years NS1 titres of > 11 was seen in 8(42.1%) of the children.P value 
was 0.323 which was not significant. 
 
  
 72 
Table 10 
Distribution of study population according to Clinical diagnosis 
Clinical diagnosis Number Percentage 
Mild dengue 128 51.2 
Moderate dengue 97 38.8 
Severe dengue 25 10 
Total 250 100 
 
Figure 18 Distribution of study population according to Clinical diagnosis 
 
Table 10 and figure 18 shows the distribution of study population according 
to clinical diagnosis. Out of 250 children Mild dengue was seen in 128(51.2%), 
Moderate dengue was seen in 97(38.8%) and Severe dengue was seen in 25(10%) 
of the children. 
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Table 11 
Distribution of study population according to Serology 
Type of dengue Number Percentage 
Primary dengue 122 48.8 
Secondary dengue 128 51.2 
Total 250 100 
 
Figure 19 Distribution of study population according to Serology 
 
 
Table 11 and figure 19 showed the distribution of study population according to 
serology. Out of 250 children 122(48.8%) had primary dengue and 128(51.2%) 
had secondary dengue fever. 
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Table 12 
Association between age group and clinical diagnosis 
 Mild dengue Moderate 
dengue 
Severe dengue P value 
< 5 years 68(56.7) 40(33.3) 12(10)  
0.61(NS) 6-10 years 34(47.9) 30(42.3) 7(9.9) 
11-15 years 16(40) 19(47.5) 5(12.5) 
>15 years 10(52.6) 8(42.1) 1(5.3) 
 
Figure 20 Association between age group and clinical diagnosis 
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Table 12 and figure 20 showed the association between age group and 
clinical diagnosis. In age group less than 5 years, Mild dengue was seen in 
68(56.7%) of the children, Moderate dengue was seen in 40(33.3%)of the children, 
Severe dengue was seen in 12(10%) of the children. In the age group of 6 to 10 
years, Mild dngue was seen in 34(47.9%) of the children, Moderate dengue was 
seen in 30(42.3%) of the children, Severe dengue was seen in 7(9.9%) of the 
children. In the age group of 11 to 15 years , Mild dengue was seen in 16(40%) of 
the children, Moderate dengue was seen in 19(47.5%) of the children, Severe 
dengue was seen in 5(12.5%) of the children. In the age group of > 15 years, Mild 
dengue was seen in 10(52.6%) of the children, Moderate dengue was seen in 
8(42.1%) of the children and severe dengue was seen in 1(5.3%)of the children. p 
value was 0.61 which was not statistically significant. 
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Table 13  
Agreement  between NS1 titre levels and clinical diagnosis 
NS1 levels Clinical diagnosis P value 
Mild dengue Moderate 
dengue 
Severe 
dengue  
 
0.525 
< 9 42(51.9) 33(40.7) 6(7.4) 
9-11 43(58.1) 27(36.5) 4(5.4) 
>11 43(45.3) 37(38.9) 15(15.8) 
 
Figure 21 Agreement between NS1 titre levels and clinical diagnosis 
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Table 13 and figure 21 shows the Titre levels  of <9 was seen in 33(40.7%) of 
children with moderate dengue, titre values of 9 to 11 was seen in 27(36.5%) of the 
children diagnosed with moderate dengue, titre values of > 11 was seen 
in37(38.9%) of children diagnosed with moderate dengue Titre levels of < 9 was 
seen in 6 children(7.4%) of children diagnosed with severe dengue, titre values of 
9 to 11 was seen in 4 (5.4%) children diagnosed with severe dengue, titre values of 
> 11 was seen in children 15 (15.8%) of children diagnosed with severe dengue. 
The p value was 0.525 which was not statistically significant. 
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DISCUSSION 
Dengue fever is a recently emerging health problem with increasing 
epidemics every year. The revised World Health Organization dengue fever 
guidelines 2011 have stressed the need for early diagnosis and treatment to reduce 
the mortality due to severe dengue infection. 
However there are no proven or clear interventions or modalities to predict 
the severity of dengue fever in children 
In our study we have aimed at developing  a predictor of severity of dengue 
fever.  
This is a cross sectional study which was conducted in a tertiary care 
teaching hospital in Coimbatore, Tamilnadu. We have aimed to find out the 
association between NS1 Antigen titre levels and the severity of dengue fever in 
childen between January 2016 to May 2017. NS1 titre levels were measured using 
ELISA method and it was correlated with Clinical severity. 
Demographic distribution of the study 
Age  
Majority of our study population (48%) were less than 5 years of age and nearly 
75% of our study population was less than 10 years. The mean age of children 
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admitted was 6.8 + 4.93years. This was similar to Borez et al and Sriram Potha 
Pregada et al 
(59)
 study (the mean age group of children were respectively 6.9 years 
and 6.8 years.) 
Sex distribution 
Our study population had slightly male predominance, the male: female ratio 
were  1.1: 1. This finding was similar to Sriram Potha Pregada et al 
(59)
 study  
Admission status 
Most of our children were treated as inpatients (89.6%) and the remaining 
10.4% were treated as out patients. This was contrary to Veasna duong et al
(60)
 
study where all the study population were inpatients. The children who were not 
admitted were mild dengue children without any warning signs. 
Observation of NS1 Antigen testing and the day of illness 
NS1  Antigen was  found to be positive in158(63.2%) children when  done 
in less than 3 days of illness. Ns1 antigen was positive in 92 children (36.8%) 
when done on 4 to 5 days of illness.  Parnavitane et al 
(41)
 showed that NS1 Assay 
was found highly sensitive for dengue infection when done within day 5 of illness 
and similar observation was found in our study.  
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Severity of illness 
In our study there were 51.2% of mild dengue, 38.2% of moderate dengue 
and only 10% were severe dengue. This can be attributed to the normal pattern of 
infectious diseases, where milder illnesses are more common than severe forms of 
the disease. Similar results were noticed by Alcon et al and Jeanne et al in their 
studies 
(53, 54).
 
Association between study population and serology 
Out of 250 children included 122 (48.8%) had primary dengue and 128 
(51.2%) had secondary dengue fever.  
Association between age group and clinical diagnosis 
When the association between age group and clinical diagnosis of mild,  
moderate and severe dengue was analysed it was observed that in children less than 
5 years of age, Mild dengue was seen in 56.7% of the children, Moderate dengue 
was seen in 40% of the children and 10% of the children had severe dengue.In the 
age group of children from 6 to 10 years mild dengue was seen in 47.9% of the 
children, moderate dengue was seen in 42.3% of the children and severe dengue 
was seen in 9.9% of the children. In children between age group of 11 to 15 years 
mild dengue was seen in40% of the children, moderate dengue was seen in 47.5% 
of the children and severe dengue was seen in 12.5% of the children. In children  
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more than 15 years, mild dengue was seen in 52.6% of the children, 42.1% of the 
children had moderate dengue and severe dengue was seen in 5.3% of the children. 
Statistical correlation was done which showed a p value of 0.61 which was not 
significant. However  majority of the children were categorized as mild dengue and 
the common age of presentation was less than 5 years. Sriram et al 
(59) 
did a similar 
study NS1 Ag was positive in 217 (83.1%) cases and among them non-severe 
dengue and severe dengue was 143 cases (65.9%) and 74 cases (34.1%) 
respectively.  
Association between age group and ns1 titre values 
 In the age group of less than 5 years titre values of 9 to 11  was seen in 
32(26.7%)of the children, in the age group of 6 to 10 years titre values of 9 to 11 
was seen in 26(36.6%) of the children. In the age group of 11 to 15 years titre 
values of 9 to 11 was seen in12(30%) of the children, in age group of > 15 years 
titre values of 9 to 11 was seen in 4 (21.1%) children. 
In age group of less than 5 years titres titre values of less than9 was seen in 
43 children(35.8%) and in age group of 6 to 10 years titre values of  less than 9 
was seen in 23 children( 32.4%). In children with age group of 11 to 15 years titre 
values of <9 was seen in 8 (20%)  children. Children with age group of 11 to 15 
years NS1 antigen titre values of <9 was seen in 7(36.8%) children 
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In the age group of children <5 years titre values of> 11 was seen in 
45(37.5%) children, in children with age group of 6 to 10 years titre values > 11 
was seen in 22(31%) of the children. In age group of children between 11 to 15 
years titre values of > 11 was seen in 20(50%) of the children. In age group of 
children > 15 years NS1 titres of > 11 was seen in 8(42.1%) of the children. P 
value was 0.323 which was not statistically significant. Similar observation was 
seen in study conducted by Dutta et al study 
(61)
 where a wide range of pediatric 
population was included and NS1 Antigen levels with severity of dengue fever did 
not have any statistical significance. This study was done in teaching hospital in 
South India which used the similar J Mithra kit for estimation of titres similar to 
our study. 
Association between ns1 titres and clinical diagnosis 
When the association between NS1 titre levels and clinical diagnosis was 
correlated, Titre levels of <9 was seen in 33(40.7%) of children with moderate 
dengue, titre values of 9 to 11 was seen in 27(36.5%) of the children diagnosed 
with moderate dengue, titre values of > 11 was seen in37(38.9%) of children 
diagnosed with moderate dengue. Titre levels of < 9 was seen in 6 children(7.4%) 
of children diagnosed with severe dengue, titre values of 9 to 11 was seen in 4 
(5.4%) children diagnosed with severe dengue, titre values of > 11 was seen in 
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children 15 (15.8%) of children diagnosed with severe dengue. The p value was 
0.525 which was not statistically significant. 
Our study observation was similar to Study done by Kosiah et al 
(62)
 in 
Indonesia which showed that NS1 Antigen levels had a poor correlation with 
severity of dengue fever. 
However the above mentioned study was done only in critically ill children 
whereas in our study we tried to correlate the antigen titres with all children 
categorised as mild, moderate and severe dengue 
Our study semi quantification of NS1 titres was done and titres were not exactly 
quantitated in contrary to the above mentioned study. 
Hence we conclude that NS1 Antigen ELISA titres cannot be used as a 
predictor  of severity in children. 
Quantification of NS1 Assays can be  recommended which may be warrant 
early prediction of dengue fever  and help in effective management of 
management. 
Further more studies on the utility of NS1 Assay and other interventions 
may  be useful in predicting the severity of dengue fever  and to reduce further 
complications and mortality. 
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CONCLUSION 
In our study we conclude that NS1 Antigen ELISA  titres may not be useful 
in predicting the severity of dengue fever in children and further research is 
warranted for early identification of severity of  dengue which can help in 
significant reduction in mortality. 
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LIMITATIONS 
However our study had few limitations that NS1 antigen Assay was not 
quantitated and NS1 Assay was not performed uniformly on one particular day of 
illness which would have warranted more clinical significance. 
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PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
 
I  Lavanya M., Jayavardhana A., Appalu Raju, am / a carrying out a study on the topic: 
Correlation of NS1 antigen assay with the severity and outcome of dengue fever in children 
 
as part of my / research project being carried out under the aegis of the Department of: 
Peadiatrics   
 
(Applicable to students only): My research guide is: DR. A.JAYAVARDHANA 
 
The justification for this study is: This study is done to justify the utility of NS 1 antigen in the 
management of fever in children in a resource limited set up 
 
The objectives of this study are:  
 
Primary Objective: To assess the correlation between NS1 antigen and severity of the disease 
and outcome in children 
 
Secondary Objective: To find the correlation between NS 1 antigen and severity of dengue fever 
 
 
Sample size: 100.  
 
Study volunteers / participants are (specify population group & age group): ____Children 
diagnosed as dengue fever less than 18 years of age________________.  
 
Location: ____PSG hospitals, Coimbatore_________________.  
 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration):____5______ minutes.  
 
Data collected will be stored for a period of ____3_ years. We will / will not use the data as part 
of another study. 
 
Health education sessions: Number of sessions: _____________. Approximate duration of 
each session:  
______________ minutes.  
 
Clinical examination (Specify details and purpose):  
 
Blood sample collection: Specify quantity of blood being drawn: ______2_____ml.  
 
No. of times it will be collected: _______1________.  
 
Whether blood sample collection is part of routine procedure or for research (study) purpose:   
 
 1. Routine procedure   
 2. Research purpose  
Specify purpose, discomfort likely to be felt and side effects, if any: 
_______________________________ 
 
Whether blood sample collected will be stored after study period: Yes /  No, it will be 
destroyed 
 
Whether blood sample collected will be sold: Yes / No  
 
Whether blood sample collected will be shared with persons from another institution: Yes / 
No 
 
Medication given, if any, duration, side effects, purpose, benefits:  
 
Whether medication given is part of routine procedure: Yes / No (If not, state reasons for giving 
this medication) 
 
Whether alternatives are available for medication given: Yes / No (If not, state reasons for 
giving this particular medication) 
 
Final interview (specify approximate duration):____5_____ mts. If photograph is taken, 
purpose:  
 
Benefits from this study:  
 
Risks involved by participating in this study: Nil 
 
How the results will be used: For the interpretation of NS1 antigen assay with the severity of 
the disease in children 
 
If you are uncomfortable in answering any of our questions during the course of the interview / 
biological sample collection, you have the right to withdraw from the interview / study at 
anytime. You have the freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you so decide, will not 
result in any form of compromise or discrimination in the services offered nor would it attract 
any penalty. You will continue to have access to the regular services offered to a patient. You 
will NOT be paid any remuneration for the time you spend with us for this interview / study. 
The information provided by you will be kept in strict confidence. Under no circumstances shall 
we reveal the identity of the respondent or their families to anyone. The information that we 
collect shall be used for approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether directly related to you or 
to other participants of this study, developed during the course of this research which may relate 
to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has 
been explained to me by the investigator/s. Having understood the same, I hereby give my 
consent to them to interview me. I am affixing my signature / left thumb impression to indicate 
my consent and willingness to participate in this study (i.e., willingly abide by the project 
requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
 
  
SOP 03-V 3.0 / ANX 10-V 3.0 
 
Institutional Human Ethics Committee 
PSG Institute of Medical Sciences and Research, Coimbatore 
 
Parental Consent Form 
 
Title of Study:Correlation of NS1 antigen assay with the severity and outcome of dengue 
fever in children. 
 
Name of the Principal Investigator: Dr. Lavanya M 
 
Department:  
Your (son/daughter/child/infant/adolescent youth) is invited to participate in a study of 
(describe the study).  
 
My name is Dr.Lavanya.Mand I am a junior resident at PSG Institute of Medical Sciences and 
Research, Coimbatore. This study is (state how study relates to your program of work or your 
supervisor’s program of work).  
 
I am asking for permission to include your (son/daughter/child/infant/adolescent youth) in this 
study because  
  
I expect to have 100 (Number) participants in the study. 
If you allow your child to participate, (state who will actually conduct the research) will 
(describe the procedures to be followed.) 
 
Any information that is obtained in connection with this study and that can be identified with 
your (son/daughter/child/infant/adolescent youth) will remain confidential and will be 
disclosed only with your permission. His or her responses will not be linked to his or her name 
or your name in any written or verbal report of this research project. 
 
Your decision to allow your (son/daughter/child/infant/adolescent youth) to participate will not 
affect your or his or her present or future relationship with PSGIMS&R or PSG Hospitals  or 
(include the name of any other institution connected with this project). If you have any 
questions about the study, please ask me. If you have any questions later, call me at 
08012017880. If you have any questions or concerns about your 
(son/daughter/child/infant/adolescent youth)’s participation in this study, 
call………………………………….. 
 
You may keep a copy of this consent form. 
You are making a decision about allowing your (son/daughter/child/infant/adolescent youth) to 
participate in this study. Your signature below indicates that you have read the information 
provided above and have decided to allow him or her to participate in the study. If you later 
decide that you wish to withdraw your permission for your (son/daughter /child/ 
infant/adolescent youth) to participate in the study, simply tell me. 
 
You may discontinue his or her participation at any time. This will not affect in any way your 
future treatment in this hospital. 
 
Printed Name of (son/daughter/child/infant/adolescent youth) 
 
 
Signature of Parent(s) or Legal Guardian with Date Signature of Investigator with Date 
  
ÁÉ¢¾ ¦¿È¢Ó¨Èì ÌØ, â º¡ §¸¡ ÁÕòÐÅì ¸øæÃ¢ ÁüÚõ ¬Ã¡öîº¢ ¿¢ÚÅÉõ 
¬Ã¡öîº¢Â¢ø ÀíÌ ¦ÀÚÅ¾ü¸¡É ´ôÒ¾ø ÀÊÅõ 
7 Ó¾ø 18 ÅÂ¾¢üÌ ¯ðÀð¼ ÌÆó¨¾¸Ùì¸¡ÉÐ 
¿¡¡í¸û ±¾ü¸¡¸ ¯í¸¨Ç ºó¾¢ì¸¢§È¡õ? 
¿¡í¸û §Áü¦¸¡ûÇ þÕìÌõ ¬öÅ¢¨Éô ÀüÈ¢ ¯í¸ÙìÌ ÜÈ ¯û§Ç¡õ. ¬ö× ±ýÀÐ 
ÁÕòÐÅ÷¸û ¯¼ø ¿Äõ ÁüÚõ Å¢Â¡¾¢¸û ÌÈ¢òÐ ¾¸Åø¸û §º¸Ã¢ò¾ø ¬Ìõ. ÁÕòÐÅ÷  
Ä¡ÅýÂ¡ .§À¡, ÁüÚõ º¢Ä÷ §º÷óÐ ¿¸÷ôÒÈõ ÁüÚõ “ÌÆó¨¾¸ÙìÌ ²üÀÎõ ¾£Å¢Ã ¦¼íÌì 
¸¡öºÖìÌõ þÃò¾ò¾¢ø ¯ûÇ NS1 ¬ýÊƒÉ¢ý «Ç×¸ÙìÌõ ¯ûÇ ºõÀó¾õ ÀüÈ¢Â ¬ö×” 
ÀüÈ¢ §ÁÖõ ¾¸Åø¸û «È¢óÐ ¦¸¡ûÇ ´Õ ¬ö× §Áü¦¸¡ûÇ ¯ûÇÉ÷. «¾¨Éô ÀüÈ¢ ¿¡í¸û 
¯í¸ÙìÌ Å¢ÅÃÁ¡¸ì ÜÈ¢Â À¢ý þó¾ ¬öÅ¢ø Àí§¸üÀÐ ÀüÈ¢ ¯í¸û ¸Õò¾¢¨Éò 
¦¾Ã¢Å¢ì¸Ä¡õ.  
¿¡¡í¸û ±¾ü¸¡¸ þó¾ ¬öÅ¢¨É §Áü¦¸¡û¸¢§È¡õ? 
¿¡í¸û ¾£Å¢Ã ¦¼íÌ ¸¡öîº¨Ä Å¢¨ÃÅ¡¸ þÃò¾ò¾¢ø NS1 ¬ýÊƒÉ¢ý ãÄõ ¸ñÎÀ¢Êì¸ 
ÓÂüº¢ì¸¢§È¡õ. ±É§Å ¯í¸¨Çô §À¡ýÈ ÀÄ ÌÆó¨¾¸Ç¢¼õ ¾¸Åø §º¸Ã¢ì¸ ¯û§Ç¡õ. þó¾ 
¬öÅ¢ø ÍÁ¡÷    ÌÆó¨¾¸û ÀíÌ ¦ÀÈ ¯ûÇÉ÷. 
þó¾ ¬öÅ¢ø ¿£í¸û Àí§¸üÈ¡ø ±ýÉ ¿¼ìÌõ? 
1. ¯í¸û ¨¸Â¢Ä¢ÕóÐ 1 Ó¨È °º¢ ãÄõ þÃò¾õ ±Îì¸ôÀÎõ. 
þó¾ ¬öÅ¢É¡ø ÅÄ¢ ²üÀÎÁ¡? 
°º¢ ÌòÐõ ¦À¡ØÐ º¢È¢Ð ÅÄ¢ ²üÀÎõ. «Ð Å¢¨ÃÅ¢ø ºÃ¢Â¡¸¢ Å¢Îõ. 
þó¾ ¬öÅ¢ø Àí§¸üÀ¾¡ø ¿Äõ «¨¼Å£÷¸Ç¡? 
þø¨Ä. þ¾É¡ø ¿£í¸û ¿ÄÁ¨¼Â ÓÊÂ¡Ð. ¬É¡ø, ÁÕòÐÅ÷¸û þó¾ ¬öÅ¢ý ãÄõ 
À¢ü¸¡Äò¾¢ø ¯í¸¨Çô §À¡ýÈ ÌÆó¨¾¸ÙìÌ ¯À§Â¡¸ô ÀÎõ Å¨¸Â¢ø º¢Ä ÅÆ¢Ó¨È¸¨Çì 
¸ñÎÀ¢Êì¸Ä¡õ. 
±ø§Ä¡ÕìÌõ ±ý ¿¢¨Ä ÀüÈ¢ ¦¾Ã¢Â ÅÕÁ¡? (¿õÀ¸ò¾ý¨Á) 
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÀ¨¾ ¿¡í¸û ÁüÈÅ÷¸ÙìÌò ¦¾Ã¢Å¢ì¸ Á¡ð§¼¡õ. ¯í¸¨Çô ÀüÈ¢Â 
¾¸Åø¸¨Ç ¬öÅ¢ø ºõÀó¾ô À¼¡¾ ¿À÷¸ÙìÌò ¦¾Ã¢Å¢ì¸ Á¡ð§¼¡õ. 
þó¾ ¬ö× ±ÉìÌ ¦¸Î¾ø «øÄÐ ¬ÀòÐ Å¢¨ÇÅ¢ìÌÁ¡? 
þø¨Ä 
þó¾ ¬öÅ¢ø Àí§¸üÀ¾¡ø ±ÉìÌ ±Ð×õ ¸¢¨¼ìÌÁ¡? 
þø¨Ä 
¿£í¸û ±ÉìÌ þó¾ ¬öÅ¢ý ÓÊ×¸¨Çò ¦¾Ã¢Å¢ôÀ£÷¸Ç¡? 
þø¨Ä 
¯í¸ÙìÌ ²§¾Ûõ §¸ûÅ¢¸û ¯ûÇ¾¡? 
¿£í¸û þô¦À¡Ø§¾¡ À¢ýÉ§Ã¡ ±ó¾ §¿Ãò¾¢Öõ ¯í¸û ºó§¾¸í¸¨Çì §¸ð¸Ä¡õ. ±ýÉ¢¼§Á¡ 
«øÄÐ þó¾ ¬öÅ¢ý À¢È ¬Ã¡öîº¢Â¡Ç÷¸Ç¢¼§Á¡ ¯í¸û ºó§¾¸í¸¨Çì §¸ð¸Ä¡õ. 
þó¾ ¬öÅ¢ø ¿£í¸û Àí§¸ü¸ §ÅñÎÁ¡? 
þø¨Ä. þ¾¢ø Àí§¸ü¸¡¾¾¡ø ¯í¸¨Ç Â¡Õõ ±Ð×õ ¦ºöÂô§À¡Å¾¢ø¨Ä. ¯í¸ÙìÌ Å¢ÕôÀõ 
þø¨Ä ±ýÈ¡ø ±í¸Ç¢¼õ ¦¾Ã¢Å¢ì¸Ä¡õ. ¿£í¸û Àí§¸ü¸ Å¢ÕõÀ¢É¡Öõ ±í¸Ç¢¼õ ¦¾Ã¢Å¢ì¸Ä¡õ. 
¿£í¸û þô¦À¡ØÐ ´òÐì ¦¸¡ñÎ À¢ýÉ÷ ÁÉõ Á¡È¢ ¬öÅ¢Ä¢ÕóÐ Å¢ÄÌÅ¾¡É¡ø Å¢Ä¸Ä¡õ 
±ýÀ¨¾Ôõ ÁÉ¾¢ø ¦¸¡ûÇ×õ. þÐ ¿£í¸û À¢ü¸¡Äò¾¢ø ÁÕòÐÅÁÉ¢Â¢ø ¦ÀÚõ º¢¸¢î¨º¨Â ±ó¾ 
Å¢¾ò¾¢Öõ À¡¾¢ì¸¡Ð ±ýÀ¨¾Ôõ ¿¡í¸û ¯í¸ÙìÌ ¦¾Ã¢Å¢òÐì¦¸¡ûÇ Å¢ÕõÒ¸¢§È¡õ. 
¿¡ý Â¡Ã¢¼õ §Àº «øÄÐ ºó§¾¸õ §¸ð¸ ÓÊÔõ? 
¿£í¸û þô¦À¡Ø§¾¡ À¢ýÉ§Ã¡ ±ó¾ §¿Ãò¾¢Öõ ¯í¸û ºó§¾¸í¸¨Çì §¸ð¸Ä¡õ. ±ýÉ¢¼§Á¡ 
«øÄÐ þó¾ ¬öÅ¢ý À¢È ¬Ã¡öîº¢Â¡Ç÷¸Ç¢¼§Á¡ ¯í¸û ºó§¾¸í¸¨Çì §¸ð¸Ä¡õ. 
¯í¸ÙìÌ Å¢ÕôÀõ þø¨Ä ±ýÈ¡ø ±í¸Ç¢¼õ ¦¾Ã¢Å¢ì¸×õ. ¿£í¸û Àí§¸ü¸ Å¢ÕõÀ¢É¡ø 
±í¸Ç¢¼õ ¦¾Ã¢Å¢ì¸×õ. þ¾É¡ø ¿£í¸û À¢ü¸¡Äò¾¢ø ÁÕòÐÅÁÉ¢Â¢ø ¦ÀÚõ º¢¸¢î¨º¨Â ±ó¾ 
Å¢¾ò¾¢Öõ À¡¾¢ì¸¡Ð ±ýÀ¨¾Ôõ ¿¡í¸û ¯í¸ÙìÌ ¦¾Ã¢Å¢òÐì¦¸¡ûÇ Å¢ÕõÒ¸¢§È¡õ. 
´ôÒ¾ø ¸ÄóÐ¨ÃÂ¡¼ø ¿¼ò¾¢Â ¿ÀÃ¢ý ¨¸¦Â¡ôÀõ 
¿¡ý ___________________ ±ýÛõ ÌÆó¨¾ìÌô ÒÃ¢Ôõ ¦Á¡Æ¢Â¢ø þó¾ ¬öÅ¢¨Éô ÀüÈ¢ 
Å¢ÅÃ¢òÐû§Çý. ÌÆó¨¾ þó¾ ¬öÅ¢ø ÀíÌ ¦ÀÈ ´ôÒì ¦¸¡ñÎûÇÐ. 
 
¸ÄóÐ¨ÃÂ¡¼ø ¦ºö¾Å÷ ¨¸¦Â¡ôÀõ __________________ §¾¾¢ 
¸ÄóÐ¨ÃÂ¡¼ø ¦ºö¾Å÷ ¦ÀÂ÷ ______________________ 
À¡¸õ 2-´ôÒ¾ø º¡ýÈ¢¾ú 
¿¡ý þó¾ ¾¸Å¨Äô ÀÊòÐò ¦¾Ã¢óÐ ¦¸¡ñ§¼ý (ÀÊòÐò ¦¾Ã¢Å¢ì¸ôÀðÎû§Çý). ±ÉÐ 
ºó§¾¸í¸¨Çì §¸ðÎ ¦¾Ç¢× ÀÎò¾¢ì ¦¸¡ñ§¼ý. À¢ü¸¡Äò¾¢Öõ ±ÉÐ ºó§¾¸í¸¨Çì 
§¸ð¸Ä¡õ ±ýÀ¨¾Ôõ «È¢óÐ ¦¸¡ñ§¼ý. 
¿¡ý þó¾ ¬öÅ¢ø ÀíÌ ¦ÀÈ Å¢ÕõÒ¸¢§Èý 
(«øÄÐ) 
±ÉìÌ þó¾ ¬öÅ¢ø Àí§¸ü¸ Å¢ÕôÀõ þø¨Ä, ¿¡ý ¸£ú ¸ñ¼ ´ôÒ¾ø ÀÊÅò¾¢ø 
¨¸¦ÂØò¾¢¼Å¢ø¨Ä __________________ (ÌÆó¨¾Â¢ý ¨¸¦Â¡ôÀõ) 
ÌÆó¨¾ ´ôÒì¦¸¡ñ¼¡ø ÁðÎõ 
1. ÌÆó¨¾Â¢ý ¦ÀÂ÷ 
2. ÌÆó¨¾Â¢ý ¨¸¦Â¡ôÀõ 
3. §¾¾¢ 
ÀÊôÀÈ¢Å¢øÄ¡¾Å÷¸Ç¡¸ þÕó¾¡ø 
´Õ ÀÊò¾ º¡ðº¢ (ÌÆó¨¾Â¢ý ¦Àü§È¡ÃøÄ¡¾, Àí§¸üÀÅÃ¡ø §¾÷ó¦¾Îì¸ôÀð¼ ´Õ ¿À÷) 
¨¸¦Â¡ôÀÁ¢¼§ÅñÎõ. ÀÊôÀÈ¢Å¢øÄ¡¾Å÷ ¾í¸û ¨¸¿¡ð¨¼ô À¾¢ì¸§ÅñÎõ. ÌÆó¨¾Â¢¼õ 
´ôÒ¾ø ¦ÀÚõ ¦À¡ØÐ þó¾ô ÀÊÅõ ÀÊì¸ô Àð¼¨¾ ¿¡ý ¯¼É¢ÕóÐ ¸ÅÉ¢ò§¾ý. Àí§¸üÀ¡Ç÷ 
¾ÉÐ ºó§¾¸í¸¨Çì §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ûÇ Å¡öôÀÇ¢ì¸ôÀð¼Ð ±ýÀ¨¾ «È¢óÐ ¦¸¡ñ§¼ý. 
Àí§¸üÀ¡Ç÷ ¾ÉÐ ´ôÒ¾¨Ä ¾ÉÐ ¦º¡ó¾ Å¢ÕôÀò¾¢ø ¾¡ý ¦¾Ã¢Å¢ò¾¡÷ ±ýÚ ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
º¡ðº¢Â¢ý ¦ÀÂ÷ ______________     Àí§¸üÀÅÃ¢ý ¨¸¿¡ðÎ 
º¡ðº¢Â¢ý ¨¸¦ÂØòÐ ______________ 
§¾¾¢ ________________ 
¿¡ý Àí§¸üÀ¡ÇÕìÌ ´ôÒ¾ø ÀÊÅò¨¾ ÓØÅÐõ ÀÊòÐì ¸¡ðÊ§Éý / ÀÊòÐì ¸¡ðÊÂ¨¾ 
¸ÅÉ¢ò§¾ý. Àí§¸üÀ¡Ç÷ ¾ÉÐ ºó§¾¸í¸¨Çì §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ûÇ Å¡öôÀÇ¢ì¸ôÀðð¼Ð 
±ýÀ¨¾ «È¢óÐ ¦¸¡ñ§¼ý. Àí§¸üÀ¡Ç÷ ¾ÉÐ ´ôÒ¾¨Ä ¾ÉÐ ¦º¡ó¾ Å¢ÕôÀò¾¢ø ¾¡ý 
¦¾Ã¢Å¢ò¾¡÷ ±ýÚ ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
¬öÅ¡ÇÃ¢ý ¦ÀÂ÷ _____________ 
  
¦Àü§È¡÷ ´ôÒ¾ø ÀÊÅõ 
¾¨ÄôÒ: 
ÌÆó¨¾¸ÙìÌ ²üÀÎõ ¾£Å¢Ã ¦¼íÌì ¸¡öºÖìÌõ þÃò¾ò¾¢ø ¯ûÇ NS1 ¬ýÊƒÉ¢ý 
«Ç×¸ÙìÌõ ¯ûÇ ºõÀó¾õ ÀüÈ¢Â ¬ö× 
 
¯í¸û (Á¸ý / Á¸û / ÌÆó¨¾¸û) þó¾ ¬ö×ìÌ «¨Æì¸¢ý§Èý. ¿¡ý ÌÆó¨¾¸ÙìÌ 
²üÀÎõ ¾£Å¢Ã ¦¼íÌì ¸¡öºÖìÌõ þÃò¾ò¾¢ø ¯ûÇ NS1 ¬ýÊƒÉ¢ý «Ç×¸ÙìÌõ ¯ûÇ 
ºõÀó¾õ ÀüÈ¢ §¸¡ÂõÒòàÃ¢ø ¬ö× ¿¼ò¾ ¯û§Çý.  
 
±ý ¦ÀÂ÷ ÁÕ. Ä¡ÅñÂ¡ .§À¡, â º¡ §¸¡ ÁÕòÐÅì ¸øæÃ¢Â¢ø ÌÆó¨¾¸û ¿Äô À¢Ã¢Å¢ø 
ƒ£É¢Â÷ ¦Ãº¢¦¼ý¼¡¸ À½¢ÒÃ¢¸¢§Èý. þó¾ ¬ö× ±ÉÐ ÀÊôÀ¢ý ÓØ¨ÁÂ¡É â÷ò¾¢ìÌ 
«Åº¢ÂÁ¡É¾¡Ìõ. 
¿¡ý þó¾ ¬öÅ¢ø ¯í¸û (Á¸ý / Á¸û / ÌÆó¨¾¸û) §º÷ì¸ «ÛÁ¾¢ §¸ð¸¢§Èý, ²¦ÉÉ¢ø 
¿¡ý þó¾ ¬öÅ¢ø     ÌÆó¨¾¸û Àí§¸üÀ¡÷¸û ±ýÚ ±¾¢÷À¡÷ì¸¢§Èý.  
 
¿£í¸û «ÛÁÐÂÇ¢ò¾¡ø, ¿¡ý «øÄÐ ÀÂ¢üº¢ ¦ÀüÈ ¿À÷¸û ´Õ §¸ûÅ¢ôÀÊÅõ «Ç¢ô§À¡õ. 
 
¯í¸û ÌÆó¨¾¸¨Çô ÀüÈ¢ þó¾ ¬öÅ¢ø ¸ñ¼È¢Ôõ ÓÊ×¸û Á¢¸×õ ¿õÀ¢ì¸ìÌÈ¢Â¾¡¸ 
¨Åì¸ôÀÎõ. ¯í¸û «ÛÁ¾¢Â¢ý ¦ÀÂÃ¢ø ÁðÎ§Á ¦ÅÇ¢Â¢¼ôÀÎõ. ¯í¸û ÌÆó¨¾Â¢ý 
À¾¢ø¸§Ç¡ «øÄÐ ¯í¸û ÌÆó¨¾Â¢ý ¦ÀÂ§Ã¡ ±ó¾ ±ØòÐ ÅÊÅÁ¡¸§Å¡ «øÄÐ Å¡öÅÆ¢ 
ÀÊÅÁ¡¸§Å¡ ¦ÅÇ¢Â¢¼ôÀ¼¡Ð. 
 
¯í¸û «ÛÁ¾¢Â¡ø, ¯í¸Ùì§¸¡ ¯í¸û À¢û¨Ç¸Ùì§¸¡ â º¡ §¸¡ ÁÕòÐÅÁ¨ÉÔ¼É¡É 
¯ÈÅ¢ø ±ó¾ À¡¾¢ôÒõ ²üÀ¼¡Ð. ¯í¸ÙìÌ ¬öÅ¢ø ²§¾Ûõ §¸ûÅ¢¸û þÕó¾¡ø ±ý¨É 
§¸Ùí¸û. ¯í¸ÙìÌ À¢ü¸¡Äò¾¢ø ²§¾Ûõ ³Âí¸û þÕó¾¡ø þó¾ ±ñ¨½ «¨Æì¸×õ 
(8012017880). ¯í¸û ÌÆó¨¾Â¢ý Àí§¸üÀ¢ø ²§¾Ûõ ºó§¾¸õ ¯ý¦¼É¢ø þó¾ ±ñ½¢üÌ 
(0422-2570170, Extn. 5818) «¨Æì¸×õ 
 
þó¾ ´ôÒ¾ø ÀÊÅò¾¢ø ´Õ À¢Ã¾¢¨Â ¿£í¸û ¦ÀüÚì¦¸¡ûÇÄ¡õ. ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ 
¯í¸û (Á¸ý / Á¸û / ÌÆó¨¾¸û) ÓÊ×¦ºö¸¢È£÷¸Ç¡É¡ø ¸£§Æ ¨¸¦ÂØò¾¢ðÎ «¾ü¸¡É 
´ôÒ¾¨Ä «Ç¢ì¸ §ÅñÎõ. ¯í¸û ¨¸¦ÂØò¾¢ý ¦À¡Õû Â¡¦¾É¢ø ¿£í¸û þó¾ ÀÊÅò¾¢ø 
¯ûÇ ¾¸Åø¸û «¨Éò¨¾Ôõ ÓØ¨ÁÂ¡¸ ÀÊòÐ ¯í¸û (Á¸ý / Á¸û / ÌÆó¨¾¸û) þ¾¢ø 
Àí§¸ü¸ «ÛÁ¾¢ ÅÆíÌ¸¢È£÷¸û ±É «÷ò¾õ. 
À¢ü¸¡Äò¾¢ø þó¾ ¬öÅ¢øÄ¢ÕóÐ ¯í¸û (Á¸ý / Á¸û / ÌÆó¨¾¸û) Àí§¸ü¸ §Åñ¼¡õ ±ýÚ 
±ýÉ¢É¡ø ±ÉìÌ «È¢Å¢ì¸×õ. ¯í¸û Å¢ÕôÀÁ¢ý¨Á¨Â ±ó¦¿Ãõ §ÅñÎ¦ÁýÈ¡Öõ 
¦¾Ã¢Å¢ì¸×õ. þÐ ¯í¸û ÅÕí¸¡Ä º¢ìî¨ºÓ¨È¨Â ±ó¾ Å¢¾ò¾¢Öõ À¡¾¢ì¸¡Ð. 
 
¦ÀÂ÷ (Á¸ý / Á¸û / ÌÆó¨¾¸û):  
 
 
¦Àü§È¡÷ «øÄÐ ºð¼ôâ÷ÅÁ¡É À¡Ð¸¡ÅÄÃ¢ý ¨¸¦Â¡ôÀõ / §¾¾¢ 
 
 
¬öÅ¡ÇÃ¢ý ¨¸¦Â¡ôÀõ / §¾¾¢ 
 
  
PROFORMA 
                                                                              
Name 
Age      
Sex 
Weight  
Height 
Address 
 
Fever           Yes/No 
 
Duration  
Retroorbital pain  Yes/No 
 
Arthralgia  Yes/No 
 
Head ache   Yes/No 
 
Rashes         Yes/No 
 
Myalgia       Yes/No 
 
 
 
VITALS 
 •  Temp BP  mm/hg     Heart rate   /min        Resp rate / min 
 
• Urine output    ml/kg/hour          Capillary refilling time  
 
• Pulse volume      
 
• Peripheries                warm/ cold  
• Head  ache                   yes/no 
• Rashes                          yes/no 
• Myalgia                         yes/no 
 
VITALS 
 
•  Temp              BP                mm/hg          Heart rate   /min     Resp   
     
• Urine output    ml/kg/hour               Capillary refilling time  
 
 
• Pulse volume     
 
• Peripheries warm/ cold 
                                                     
  
INVESTIGATIONS: 
 
• Platelet count-  
 
• Haematocrit- 
 
• Haemoglobin- 
 
• Total count- 
 
• NS1 Antigen          Yes/No 
 
         
Titre value 
                 
 Day of illness           
 
• Dengue serology  
   IgM  Yes/ No         Titre 
 
                                          IgG   Yes/No           Titre 
 
 
SL.NO. AGE NS1 TITRE DIAGNOSIS DAY OF ILLNESS ICU ADMN. SEROLOGY
1 3 >11 Severe 4 Yes secondary
2 9 <9 Mild 1 primary
3 5 9 – 11 Moderate 5 secondary
4 1 >11 Mild 4 secondary
5 7 <9 Moderate 2 primary
6 8 9 – 11 Mild 5 secondary
7 3 9 – 11 Severe 3 Yes primary
8 17 >11 Mild 1 primary
9 6 <9 Moderate 3 secondary
10 3 <9 Moderate 5 primary
11 12 9 – 11 Mild 2 secondary
12 15 >11 Severe 4 Yes primary
13 4 9 – 11 Mild 5 secondary
14 2 9 – 11 Moderate 2 primary
15 13 >11 Mild 1 primary
16 17 <9 Moderate 3 secondary
17 3 9 – 11 Mild 5 primary
18 13 9 – 11 Severe 3 Yes secondary
19 2 <9 Moderate 4 primary
20 7 9 – 11 Mild 2 secondary
21 2 >11 Moderate 1 secondary
22 1 9 – 11 Moderate 4 primary
23 9 <9 Mild 5 secondary
24 16 >11 Mild 1 primary
25 13 ( Moderate 3 primary
26 2 <9 Mild 2 primary
27 1 >11 Severe 4 Yes secondary
28 6 <9 Mild 1 primary
29 7 >11 Moderate 3 secondary
30 17 >11 Moderate 2 secondary
31 4 >11 Mild 4 secondary
32 2 <9 Moderate 5 primary
33 7 <9 Mild 1 primary
34 8 9 – 11 Moderate 2 secondary
35 2 9 – 11 Mild 5 primary
36 13 <9 Moderate 4 secondary
37 14 >11 Severe 3 Yes primary
38 17 9 – 11 Moderate 1 secondary
39 6 9 – 11 Mild 3 primary
40 9 <9 Moderate 4 primary
41 1 9 – 11 Moderate 5 secondary
42 3 <9 Mild 2 primary
43 2 <9 Mild 3 secondary
44 6 9 – 11 Moderate 2 secondary
45 17 >11 Moderate 2 primary
46 12 <9 Mild 1 secondary
47 5 9 – 11 Moderate 4 primary
48 2 <9 Severe 3 Yes secondary
49 14 >11 Moderate 1 secondary
50 16 >11 Mild 5 primary
51 17 <9 Moderate 2 primary
52 3 9 – 11 Moderate 5 secondary
53 2 9 – 11 Mild 1 secondary
54 5 <9 Mild 4 primary
55 1 >11 Moderate 1 secondary
56 13 >11 Severe 3 Yes secondary
57 3 >11 Moderate 1 secondary
58 1 <9 Mild 3 primary
59 7 >11 Mild 4 secondary
60 5 >11 Moderate 5 primary
61 8 <9 Mild 1 secondary
62 9 9 – 11 Moderate 3 primary
MASTER CHART
SL.NO. AGE NS1 TITRE DIAGNOSIS DAY OF ILLNESS ICU ADMN. SEROLOGY
63 1 <9 Severe 4 Yes secondary
64 17 <9 Mild 1 primary
65 3 9 – 11 Mild 2 secondary
66 7 >11 Moderate 4 secondary
67 4 >11 Mild 5 primary
68 2 9 – 11 Moderate 1 secondary
69 1 9 – 11 Mild 3 primary
70 8 >11 Severe 4 Yes secondary
71 14 9 – 11 Mild 1 secondary
72 9 <9 Moderate 2 secondary
73 14 >11 Mild 3 primary
74 6 <9 Mild 5 primary
75 7 >11 Moderate 3 secondary
76 9 9 – 11 Mild 2 primary
77 17 >11 Moderate 4 Yes primary
78 2 9 – 11 Mild 1 primary
79 5 >11 Moderate 5 primary
80 6 <9 Moderate 2 secondary
81 2 <9 Mild 4 primary
82 14 >11 Moderate 3 secondary
83 6 9 – 11 Mild 2 secondary
84 16 <9 Mild 4 primary
85 3 >11 Moderate 1 secondary
86 4 >11 Mild 5 secondary
87 2 9 – 11 Mild 4 secondary
88 5 >11 Severe 3 Yes primary
89 17 9 – 11 Mild 1 primary
90 13 <9 Moderate 4 primary
91 4 >11 Mild 5 secondary
92 5 >11 Mild 2 primary
93 1 <9 Moderate 3 secondary
94 9 >11 Moderate 2 secondary
95 8 >11 Moderate 4 primary
96 3 >11 Mild 5 primary
97 5 9 – 11 Mild 1 secondary
98 1 >11 Severe 4 Yes secondary
99 15 9 – 11 Moderate 5 secondary
100 13 >11 Moderate 2 primary
101 12 >11 Mild 4 primary
102 4 <9 Mild 3 secondary
103 8 <9 Moderate 5 primary
104 9 9 – 11 Mild 2 primary
105 3 <9 Moderate 1 secondary
106 2 >11 Mild 7 primary
107 13 >11 Moderate 2 secondary
108 4 <9 Severe 4 Yes secondary
109 1 >11 Mild 1 primary
110 3 9 – 11 Mild 2 secondary
111 5 9 – 11 Moderate 5 secondary
112 2 <9 Mild 3 secondary
113 6 >11 Moderate 2 primary
114 7 <9 Mild 5 primary
115 9 <9 Moderate 1 secondary
116 1 9 – 11 Mild 2 primary
117 15 >11 Mild 4 secondary
118 2 <9 Severe 3 Yes primary
119 17 >11 Mild 1 secondary
120 1 9 – 11 Mild 2 primary
121 1 >11 Moderate 4 primary
122 15 >11 Moderate 5 secondary
123 2 >11 Moderate 3 primary
124 13 9 – 11 Mild 1 secondary
125 5 <9 Moderate 4 primary
SL.NO. AGE NS1 TITRE DIAGNOSIS DAY OF ILLNESS ICU ADMN. SEROLOGY
126 7 >11 Severe 3 Yes primary
127 9 <9 Moderate 4 primary
128 4 9 – 11 Moderate 1 secondary
129 2 >11 Mild 2 primary
130 1 9 – 11 Mild 5 secondary
131 2 >11 Moderate 2 primary
132 15 <9 Moderate 4 secondary
133 6 9 – 11 Mild 1 primary
134 2 9 – 11 Mild 5 secondary
135 5 <9 Moderate 2 secondary
136 8 >11 Moderate 3 primary
137 16 >11 Severe 4 Yes primary
138 9 9 – 11 Moderate 3 secondary
139 12 <9 Moderate 1 secondary
140 3 >11 Mild 2 primary
141 9 <9 Moderate 4 secondary
142 1 <9 Mild 5 primary
143 3 >11 Mild 2 secondary
144 12 <9 Moderate 3 primary
145 5 <9 Moderate 1 secondary
146 7 >11 Mild 3 primary
147 3 >11 Severe 4 Yes secondary
148 8 >11 Mild 1 primary
149 9 <9 Moderate 2 secondary
150 12 >11 Mild 5 secondary
151 3 9 – 11 Moderate 3 secondary
152 4 9 – 11 Moderate 1 secondary
153 13 9 – 11 Moderate 5 primary
154 4 <9 Mild 2 primary
155 13 >11 Moderate 4 primary
156 4 9 – 11 Mild 3 secondary
157 6 >11 Severe 4 Yes primary
158 2 >11 Mild 1 secondary
159 12 >11 Moderate 3 primary
160 4 >11 Moderate 4 secondary
161 15 <9 Mild 5 primary
162 17 <9 Mild 2 secondary
163 2 <9 Moderate 3 secondary
164 4 <9 Mild 1 primary
165 7 9 – 11 Severe 4 Yes primary
166 8 9 – 11 Mild 1 secondary
167 1 >11 Mild 2 primary
168 9 <9 Mild 4 primary
169 2 9 – 11 Moderate 2 secondary
170 8 9 – 11 Mild 3 primary
171 4 <9 Mild 1 primary
172 6 <9 Moderate 5 secondary
173 13 9 – 11 Mild 3 secondary
174 17 <9 Moderate 2 primary
175 2 9 – 11 Mild 1 secondary
176 4 >11 Mild 5 secondary
177 3 >11 Mild 2 secondary
178 12 >11 Severe 4 Yes secondary
179 13 9 – 11 Mild 1 primary
180 17 9 – 11 Moderate 4 primary
181 1 <9 Mild 1 secondary
182 9 >11 Mild 3 secondary
183 4 >11 Moderate 4 primary
184 2 >11 Mild 5 secondary
185 9 9 – 11 Mild 1 primary
186 1 >11 Mild 2 secondary
187 3 <9 Mild 5 primary
188 7 <9 Severe 3 Yes primary
SL.NO. AGE NS1 TITRE DIAGNOSIS DAY OF ILLNESS ICU ADMN. SEROLOGY
189 9 9 – 11 Mild 2 primary
190 3 >11 Mild 1 primary
191 1 >11 Moderate 3 secondary
192 2 9 – 11 Mild 5 secondary
193 6 <9 Mild 1 primary
194 8 9 – 11 Moderate 2 secondary
195 2 <9 Mild 4 secondary
196 8 >11 Mild 3 secondary
197 9 >11 Mild 1 primary
198 2 <9 Severe 4 Yes primary
199 4 <9 Mild 1 secondary
200 2 >11 Moderate 2 secondary
201 8 9 – 11 Moderate 5 primary
202 9 9 – 11 Mild 3 primary
203 2 <9 Mild 1 secondary
204 4 >11 Moderate 3 primary
205 1 >11 Mild 5 secondary
206 8 >11 Moderate 2 primary
207 4 <9 Mild 1 secondary
208 7 9 – 11 Mild 3 primary
209 9 9 – 11 Severe 4 Yes primary
210 2 >11 Mild 1 primary
211 1 >11 Mild 2 secondary
212 14 <9 Mild 4 secondary
213 2 <9 Moderate 2 secondary
214 8 9 – 11 Moderate 1 primary
215 6 >11 Moderate 3 secondary
216 2 <9 Mild 4 primary
217 3 <9 Mild 1 secondary
218 4 >11 Moderate 3 secondary
219 7 9 – 11 Mild 5 primary
220 1 <9 Mild 2 primary
221 7 9 – 11 Mild 3 secondary
222 3 >11 Severe 4 Yes primary
223 6 >11 Severe 3 Yes secondary
224 1 9 – 11 Mild 1 secondary
225 9 >11 Moderate 2 primary
226 17 <9 Mild 5 secondary
227 2 <9 Mild 3 primary
228 4 >11 Mild 2 primary
229 15 9 – 11 Moderate 1 primary
230 2 <9 Moderate 4 secondary
231 6 <9 Mild 3 primary
232 13 >11 Mild 1 secondary
233 2 <9 Moderate 5 secondary
234 12 9 – 11 Mild 2 primary
235 15 >11 Mild 4 primary
236 2 9 – 11 Mild 3 secondary
237 6 <9 Moderate 1 primary
238 7 9 – 11 Mild 3 secondary
239 9 >11 Mild 2 primary
240 8 9 – 11 Moderate 4 primary
241 1 <9 Mild 1 secondary
242 13 9 – 11 Moderate 5 secondary
243 2 <9 Mild 3 primary
244 1 >11 Mild 2 secondary
245 5 <9 Moderate 1 primary
246 7 >11 Mild 4 secondary
247 13 >11 Moderate 1 secondary
248 4 <9 Mild 3 secondary
249 17 9 – 11 Mild 4 primary
250 12 >11 Moderate 2 secondary
